Current awareness: Pharmacoepidemiology and drug safety
Identifieur interne : 002C34 ( Istex/Corpus ); précédent : 002C33; suivant : 002C35Current awareness: Pharmacoepidemiology and drug safety
Auteurs :Source :
- Pharmacoepidemiology and Drug Safety [ 1053-8569 ] ; 2006-05.
Abstract
In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.
Url:
DOI: 10.1002/pds.1178
Links to Exploration step
ISTEX:2BCF9D936A34E785E998F7ED585930ADCE5DC2FDLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current awareness: Pharmacoepidemiology and drug safety</title></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2BCF9D936A34E785E998F7ED585930ADCE5DC2FD</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/pds.1178</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-SXHJF67B-7/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002C34</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002C34</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Current awareness: Pharmacoepidemiology and drug safety</title></analytic><monogr></monogr><series><title level="j" type="main">Pharmacoepidemiology and Drug Safety</title><title level="j" type="alt">PHARMACOEPIDEMIOLOGY AND DRUG SAFETY</title><idno type="ISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><imprint><biblScope unit="vol">15</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="i">i</biblScope><biblScope unit="page" to="xii">xii</biblScope><biblScope unit="page-count">12</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2006-05">2006-05</date></imprint><idno type="ISSN">1053-8569</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1053-8569</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>univ</json:string><json:string>clin</json:string><json:string>hosp</json:string><json:string>dermatol</json:string><json:string>oncol</json:string><json:string>pharmacoepidemiology</json:string><json:string>psychiat</json:string><json:string>serv</json:string><json:string>drug safety</json:string><json:string>coll</json:string><json:string>inst</json:string><json:string>pharmacol</json:string><json:string>pharm</json:string><json:string>psychopharmacol</json:string><json:string>clin psychopharmacol</json:string><json:string>toxicity</json:string><json:string>ophthalmol</json:string><json:string>canc</json:string><json:string>hlth</json:string><json:string>dept</json:string><json:string>cardiol</json:string><json:string>suppl</json:string><json:string>neurol</json:string><json:string>john wiley son</json:string><json:string>dept psychiat</json:string><json:string>hematol</json:string><json:string>copyright</json:string><json:string>pediat</json:string><json:string>dept dermatol</json:string><json:string>clin oncol</json:string><json:string>rheumatol</json:string><json:string>gynecol</json:string><json:string>chemotherapy</json:string><json:string>randomized</json:string><json:string>current awareness</json:string><json:string>allergy</json:string><json:string>dept internal</json:string><json:string>clin pharmacol</json:string><json:string>endocrinol</json:string><json:string>obstet</json:string><json:string>antipsychotic</json:string><json:string>jama</json:string><json:string>hypersensitivity</json:string><json:string>english abstract</json:string><json:string>epidemiol</json:string><json:string>engl</json:string><json:string>pavia</json:string><json:string>acad</json:string><json:string>case report</json:string><json:string>lymphoma</json:string><json:string>childrens</json:string><json:string>pharmacotherapy</json:string><json:string>immunol</json:string><json:string>dermatology</json:string><json:string>pharmacother</json:string><json:string>antiretroviral</json:string><json:string>pharmacovigilance</json:string><json:string>clin neuropharmacol</json:string><json:string>dept pediat</json:string><json:string>side effect</json:string><json:string>dept ophthalmol</json:string><json:string>acad dermatol</json:string><json:string>leuk lymphoma</json:string><json:string>vaccine</json:string><json:string>fetal acidosis</json:string><json:string>arch intern</json:string><json:string>pitie salpetriere</json:string><json:string>blocker therapy</json:string><json:string>coll cardiol</json:string><json:string>adverse effect</json:string><json:string>selective serotonin reuptake inhibitor</json:string><json:string>dept neurol</json:string><json:string>dept rheumatol</json:string><json:string>obstet gynecol</json:string><json:string>systematic review</json:string><json:string>adverse event</json:string><json:string>univ pavia</json:string><json:string>refractory</json:string><json:string>anaesthesia</json:string><json:string>syndrome</json:string><json:string>assistance paris</json:string><json:string>antimicrob agent chemother</json:string><json:string>antiretroviral therapy</json:string><json:string>caesarean section</json:string><json:string>serv malad</json:string><json:string>neonatal sign</json:string><json:string>univ pittsburgh</json:string><json:string>dept urol</json:string><json:string>triangle park</json:string><json:string>dept clin expt</json:string><json:string>rheumatoid arthritis</json:string><json:string>hong kong</json:string><json:string>dept psychiat behav</json:string><json:string>young child</json:string><json:string>baskent univ</json:string><json:string>breast cancer</json:string><json:string>dept emergency</json:string><json:string>oral contraceptive</json:string><json:string>utero exposure</json:string><json:string>dept cardiol</json:string><json:string>dept obstet gynecol</json:string><json:string>coll pharm</json:string><json:string>spinal anaesthesia</json:string><json:string>clinical trial</json:string><json:string>intern</json:string><json:string>inhibitor</json:string><json:string>ontario</json:string><json:string>blvd</json:string><json:string>radboud univ</json:string><json:string>biostat epidemiol</json:string><json:string>rockville pike</json:string><json:string>vaccine adverse event</json:string><json:string>univ florida</json:string><json:string>depressive agent</json:string><json:string>royal free</json:string><json:string>baylor coll</json:string><json:string>randomized trial</json:string><json:string>healthy volunteer</json:string><json:string>aarhus univ hosp</json:string><json:string>autonomic agent</json:string><json:string>pharm practice</json:string><json:string>health syst pharm</json:string><json:string>henri mondor</json:string><json:string>univ london</json:string><json:string>clin microbiol</json:string><json:string>dept endocrinol</json:string><json:string>datum mining</json:string><json:string>arch ophthalmol</json:string><json:string>cardiovasc intervent radiol</json:string><json:string>urol nephrol</json:string><json:string>acute myocardial infarction</json:string><json:string>dept ophthalmol visual</json:string><json:string>dobutamine contrast stress echocardiography</json:string><json:string>robert koch</json:string><json:string>claude vellefaux</json:string><json:string>pilot study</json:string><json:string>dept pharm</json:string><json:string>risk factor</json:string><json:string>buenos aire</json:string><json:string>diabetes care</json:string><json:string>hypersensitivity syndrome</json:string><json:string>adverse drug reaction</json:string><json:string>clin pharmacol unit</json:string><json:string>toxic epidermal necrolysis</json:string><json:string>univ heidelberg</json:string><json:string>addict mental hlth</json:string><json:string>univ messina</json:string><json:string>chronic schizophrenia</json:string><json:string>antipsychotic treatment</json:string><json:string>chinese univ hong kong</json:string><json:string>parkinson disease</json:string><json:string>piazza botta</json:string><json:string>dept oncol</json:string><json:string>brigham womens hosp</json:string><json:string>antiepileptic drug</json:string><json:string>univ hosp gasthuisberg</json:string><json:string>cancer treatment case</json:string><json:string>brit columbia</json:string><json:string>refractory multiple myeloma</json:string><json:string>risk management strategy</json:string><json:string>bone marrow transplant</json:string><json:string>univ texas</json:string><json:string>anderson canc</json:string><json:string>holcombe blvd</json:string><json:string>effective treatment</json:string><json:string>metastatic colorectal cancer</json:string><json:string>dept hematol</json:string><json:string>dept dermatol venerol</json:string><json:string>hosp univ</json:string><json:string>acneiform eruption</json:string><json:string>hematol oncol</json:string><json:string>northwestern univ</json:string><json:string>important drug interaction</json:string><json:string>cerebral aneurysm</json:string><json:string>attikon univ hosp</json:string><json:string>anesth analg</json:string><json:string>thromb haemost</json:string><json:string>prospective randomized trial</json:string><json:string>anesth reanim</json:string><json:string>antiretroviral treatment</json:string><json:string>ischemic colitis</json:string><json:string>dept radiol</json:string><json:string>potential failure</json:string><json:string>contraceptive efficacy</json:string><json:string>wale hosp</json:string><json:string>smallpox vaccination</json:string><json:string>antipsychotic drug</json:string><json:string>univ wale hosp</json:string><json:string>multiple sclerosis</json:string><json:string>drug today</json:string><json:string>interval prolongation</json:string><json:string>contact dermatitis</json:string><json:string>dept haematol</json:string><json:string>antirheumatic drug</json:string><json:string>dept clin pharmacol</json:string><json:string>intensive care</json:string></teeft></keywords><articleId><json:string>PDS1178</json:string></articleId><arkIstex>ark:/67375/WNG-SXHJF67B-7</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>bibliography</json:string></originalGenre><abstract>In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</abstract><qualityIndicators><score>8.824</score><pdfWordCount>12629</pdfWordCount><pdfCharCount>78175</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>12</pdfPageCount><pdfPageSize>595 x 842 pts (A4)</pdfPageSize><pdfWordsPerPage>1052</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>152</abstractWordCount><abstractCharCount>1082</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Current awareness: Pharmacoepidemiology and drug safety</title><genre><json:string>other</json:string></genre><host><title>Pharmacoepidemiology and Drug Safety</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1099-1557</json:string></doi><issn><json:string>1053-8569</json:string></issn><eissn><json:string>1099-1557</json:string></eissn><publisherId><json:string>PDS</json:string></publisherId><volume>15</volume><issue>5</issue><pages><first>i</first><last>xii</last><total>12</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Current Awareness</value></json:item><json:item><value>Current Awareness</value></json:item></subject></host><namedEntities><unitex><date><json:string>2006</json:string><json:string>6-7-1</json:string><json:string>3-1-1</json:string><json:string>January-October 2003</json:string><json:string>1-1-5</json:string></date><geogName><json:string>Wahlen Vet Affaris Salt Lake</json:string><json:string>San</json:string><json:string>Lake City</json:string></geogName><orgName><json:string>Med Coll Georgia, Dept Psychiat</json:string><json:string>Actelion Pharmaceuticals Ltd</json:string><json:string>Denmark Hill, London SE</json:string><json:string>RADAR</json:string><json:string>Lakewood, Co</json:string><json:string>Boehringer Ingelheim Pharmaceut Inc</json:string><json:string>GlaxoSmithKline Inc</json:string><json:string>Patrick Waller Ltd</json:string><json:string>Allergan Inc</json:string><json:string>Sepracor Inc</json:string><json:string>Sons, Ltd.</json:string><json:string>Gilead Sciences Inc</json:string><json:string>US and European</json:string><json:string>Lilly Corp</json:string><json:string>Biochem</json:string><json:string>US/EPA, Neurotoxicol Div</json:string><json:string>Research on Adverse Drug Events and Reports</json:string><json:string>Pfizer Inc</json:string><json:string>US/FDA, Div Epidemiol, Off Biostat</json:string><json:string>Alcon Res Ltd</json:string><json:string>Singapore, Rep Singapore</json:string><json:string>Mexico City, DF, Mexico</json:string><json:string>Sons, Ltd</json:string><json:string>Jordan Univ Sci</json:string><json:string>US/FDA, CBER, Off Biostat</json:string><json:string>Nth Senate Blvd</json:string><json:string>Department Obstet Gynecol</json:string><json:string>All India Inst Med Sci, Dept Dermatol</json:string><json:string>Kuopio University</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Ann Pharmacother</json:string><json:string>J. Steingasse</json:string><json:string>F. Osped</json:string><json:string>Via Golgi</json:string><json:string>Carl Gustav</json:string><json:string>Div Rheumatol</json:string><json:string>A. Worthing</json:string><json:string>K. Univ</json:string><json:string>Maria Battuti</json:string><json:string>A. Karolinska</json:string><json:string>H. Bahcelievler</json:string><json:string>T. Uludag</json:string><json:string>Div Gerontol</json:string><json:string>Ann Fr</json:string><json:string>Foster G. Vicuron</json:string><json:string>C. Ullevaal</json:string><json:string>Pierce Ave</json:string><json:string>T. Saitama</json:string><json:string>Sinclair M. Monash</json:string><json:string>Div Internal</json:string><json:string>M. Univ</json:string><json:string>Univ Texas</json:string><json:string>Systematic</json:string><json:string>Logan R. Univ</json:string><json:string>Estefania Hosp</json:string><json:string>Sinai Sch</json:string><json:string>Cherry Hill</json:string><json:string>C. Upton</json:string><json:string>E. Hosp</json:string><json:string>Div Nephrol</json:string><json:string>G. Ctr</json:string><json:string>Ann Rheum</json:string><json:string>O. Univ</json:string><json:string>F. Baskent</json:string><json:string>La Timone</json:string><json:string>Care</json:string><json:string>Cheng Kung</json:string><json:string>Nova Scotia</json:string><json:string>Div Med</json:string><json:string>Sidney Kimmel</json:string><json:string>Tamar Sci</json:string><json:string>Frederick Ave</json:string><json:string>John Wiley</json:string><json:string>L. Azienda</json:string><json:string>David Geffen</json:string><json:string>Olive View</json:string><json:string>H. Attikon</json:string><json:string>Van Iersel</json:string><json:string>P. Attikon</json:string><json:string>Washington Med</json:string><json:string>B. Univ</json:string><json:string>R. Autonomous</json:string><json:string>Georges Pompidou</json:string><json:string>CHU Vaudois</json:string><json:string>Via Brigata</json:string><json:string>Ave Appia</json:string><json:string>Victoria St</json:string><json:string>D. Rene</json:string><json:string>Ann Thorac</json:string><json:string>B. Yale</json:string><json:string>Victoria Wing</json:string><json:string>Via Cherasco</json:string><json:string>Nat Cancer</json:string><json:string>La Jolie</json:string><json:string>Theodor Kutzer</json:string><json:string>Ave Claude</json:string><json:string>H. Aarhus</json:string><json:string>M. Fac</json:string><json:string>Div Cardiol</json:string><json:string>Victoria Infirm</json:string><json:string>T. Nippon</json:string><json:string>A. Hop</json:string><json:string>Pacifica Dr</json:string><json:string>Von Tirpitz</json:string><json:string>Gen Virol</json:string><json:string>Guy House</json:string><json:string>M. Chelsea</json:string><json:string>Viral Hepatitis</json:string><json:string>M. Hosp</json:string><json:string>F. Univ</json:string><json:string>R. Cent</json:string><json:string>Federico Gomez</json:string><json:string>Div Hematol</json:string><json:string>Med</json:string><json:string>Selly Oak</json:string><json:string>L. Westmead</json:string><json:string>James Cook</json:string><json:string>E. Address</json:string><json:string>Marquez</json:string><json:string>Nevada Canc</json:string><json:string>H. Shiraz</json:string><json:string>J. Univ</json:string><json:string>Edouard Herriot</json:string><json:string>S. University</json:string><json:string>J. Med</json:string><json:string>Louis Pasteur</json:string><json:string>Sheridan Rd</json:string><json:string>Div Pharmacoepidemiol</json:string><json:string>Div Pediat</json:string><json:string>Catherine Sienne</json:string><json:string>J. McMaster</json:string><json:string>Ann Intern</json:string><json:string>Div Ematol</json:string><json:string>E. Escola</json:string><json:string>B. Childrens</json:string><json:string>D. Natl</json:string><json:string>Gen Site</json:string><json:string>Virginia Commonwealth</json:string><json:string>P. Mem</json:string><json:string>Div Gastroenterol</json:string><json:string>M. Complejo</json:string><json:string>Yehuda D. Hadassah</json:string><json:string>Madison Ave</json:string><json:string>Rev</json:string><json:string>Wolmark</json:string><json:string>La Paz</json:string><json:string>Via Massarenti</json:string><json:string>Henri Mondor</json:string><json:string>Kong Eye</json:string><json:string>S. Johns</json:string><json:string>Pacific St</json:string><json:string>Via Osped</json:string><json:string>Gen Univ</json:string><json:string>Rd</json:string><json:string>Alfred Hosp</json:string><json:string>P. Univ</json:string><json:string>Div Canc</json:string><json:string>Via Paradisa</json:string><json:string>C. Address</json:string><json:string>A. Univ</json:string><json:string>W. Akad</json:string><json:string>Baptist Med</json:string><json:string>S. Royal</json:string><json:string>Umea Hosp</json:string><json:string>Francois Quesnay</json:string><json:string>J. Hosp</json:string><json:string>Div Clin</json:string><json:string>C. Univ</json:string><json:string>Case</json:string><json:string>T. Univ</json:string><json:string>I. Abarbanel</json:string><json:string>Eric Tabarly</json:string><json:string>Div Viral</json:string><json:string>Div Neonatol</json:string><json:string>Div Hepatol</json:string><json:string>La Jolla</json:string><json:string>Eneas Carvalho</json:string><json:string>Anderson Canc</json:string><json:string>Virginia Univ</json:string><json:string>F. Dept</json:string><json:string>S. Aarhus</json:string><json:string>Div Endocrinol</json:string><json:string>N. Hop</json:string><json:string>J. Northwestern</json:string><json:string>K. Rigshosp</json:string><json:string>Jude Childrens</json:string><json:string>Louis Univ</json:string><json:string>Mathias W. Univ</json:string><json:string>G. Univ</json:string><json:string>Nat Clin</json:string><json:string>Ellis Fischel</json:string><json:string>Via Boggio</json:string><json:string>CHU Nord</json:string><json:string>A. Dalhousie</json:string><json:string>P. Hamilton</json:string><json:string>King Abdulaziz</json:string><json:string>Div Dept</json:string><json:string>Div Blood</json:string><json:string>I. Univ</json:string><json:string>SUNY Buffalo</json:string><json:string>G. Ahmet</json:string><json:string>I. Address</json:string><json:string>Van Huyen</json:string><json:string>La Pitie</json:string><json:string>N. Northwestern</json:string></persName><placeName><json:string>Minneapolis</json:string><json:string>Groningen</json:string><json:string>Durham</json:string><json:string>Shiraz</json:string><json:string>Osaka City</json:string><json:string>Geneva</json:string><json:string>Stanford</json:string><json:string>Utrecht</json:string><json:string>Cagliari</json:string><json:string>Fukuoka</json:string><json:string>Buffalo</json:string><json:string>Berlin</json:string><json:string>Faubourg</json:string><json:string>Uppsala</json:string><json:string>Pavia</json:string><json:string>Ankara</json:string><json:string>Birmingham</json:string><json:string>Paris</json:string><json:string>Rochester</json:string><json:string>Middlesbrough</json:string><json:string>Swindon</json:string><json:string>Mississauga</json:string><json:string>Southampton</json:string><json:string>Cardiotoxicity</json:string><json:string>Bangalore</json:string><json:string>Miami</json:string><json:string>Switzerland</json:string><json:string>Mishima</json:string><json:string>Columbia</json:string><json:string>Alicante</json:string><json:string>Newcastle upon Tyne</json:string><json:string>Greece</json:string><json:string>United States</json:string><json:string>St Thomas</json:string><json:string>Perugia</json:string><json:string>St Savas</json:string><json:string>San Antonio</json:string><json:string>Adana</json:string><json:string>Munich</json:string><json:string>Sacramento</json:string><json:string>Joensuu</json:string><json:string>Takayama</json:string><json:string>Antwerp</json:string><json:string>Edmonton</json:string><json:string>St Andre</json:string><json:string>Brescia</json:string><json:string>Australia</json:string><json:string>Mexico</json:string><json:string>Taegu</json:string><json:string>Heidelberg</json:string><json:string>Bursa</json:string><json:string>Bern</json:string><json:string>Charleston</json:string><json:string>Korea</json:string><json:string>San Carlos</json:string><json:string>Seoul</json:string><json:string>Ulm</json:string><json:string>Columbus</json:string><json:string>Brazil</json:string><json:string>Valencia</json:string><json:string>Norway</json:string><json:string>Austria</json:string><json:string>Montreal</json:string><json:string>Pisa</json:string><json:string>Washington</json:string><json:string>Toxicity</json:string><json:string>Stavanger</json:string><json:string>Turin</json:string><json:string>Turkey</json:string><json:string>Kuopio</json:string><json:string>Richmond</json:string><json:string>Mannheim</json:string><json:string>Newark</json:string><json:string>Taiwan</json:string><json:string>Canada</json:string><json:string>Nice</json:string><json:string>DC</json:string><json:string>Taipei City</json:string><json:string>Melbourne</json:string><json:string>Oslo</json:string><json:string>Houston</json:string><json:string>Helsinki</json:string><json:string>Cardiff</json:string><json:string>Myotoxicity</json:string><json:string>NC</json:string><json:string>Argentina</json:string><json:string>San Matteo</json:string><json:string>Inchon</json:string><json:string>SC</json:string><json:string>Nottingham</json:string><json:string>Madrid</json:string><json:string>Aalborg</json:string><json:string>Newport</json:string><json:string>St Anne</json:string><json:string>Halifax</json:string><json:string>India</json:string><json:string>Reims</json:string><json:string>Seattle</json:string><json:string>Bologna</json:string><json:string>Paraguay</json:string><json:string>China</json:string><json:string>Norfolk</json:string><json:string>St Pauls</json:string><json:string>Vancouver</json:string><json:string>Messina</json:string><json:string>Cuneo</json:string><json:string>Huesca</json:string><json:string>Toronto</json:string><json:string>Atlanta</json:string><json:string>Jordan</json:string><json:string>Nantes</json:string><json:string>Hebron</json:string><json:string>Milan</json:string><json:string>Marlborough</json:string><json:string>Los Angeles</json:string><json:string>USA</json:string><json:string>Athens</json:string><json:string>Japan</json:string><json:string>Jerusalem</json:string><json:string>Woodstock</json:string><json:string>Baltimore</json:string><json:string>Ancona</json:string><json:string>Gothenburg</json:string><json:string>Vienna</json:string><json:string>Liverpool</json:string><json:string>Dijon</json:string><json:string>EPS</json:string><json:string>St Marys</json:string><json:string>Barcelona</json:string><json:string>Ferrara</json:string><json:string>Santa Cruz</json:string><json:string>Lisbon</json:string><json:string>San Francisco</json:string><json:string>Philippines</json:string><json:string>Lubeck</json:string><json:string>Waterford</json:string><json:string>Auckland</json:string><json:string>Denmark</json:string><json:string>New Zealand</json:string><json:string>Rome</json:string><json:string>Tokyo</json:string><json:string>Rochdale</json:string><json:string>St Antoine</json:string><json:string>Chicago</json:string><json:string>San Pablo</json:string><json:string>Portugal</json:string><json:string>Israel</json:string><json:string>Nagano</json:string><json:string>York</json:string><json:string>Ottawa</json:string><json:string>St Vincent</json:string><json:string>Kansas City</json:string><json:string>Hollywood</json:string><json:string>Siena</json:string><json:string>Lausanne</json:string><json:string>Ioannina</json:string><json:string>Stockholm</json:string><json:string>Padua</json:string><json:string>New Ballas</json:string><json:string>France</json:string><json:string>NJ</json:string><json:string>Quebec</json:string><json:string>Copenhagen</json:string><json:string>Salem</json:string><json:string>Sao Paulo</json:string><json:string>Marseille</json:string><json:string>Stalingrad</json:string><json:string>Indianapolis</json:string><json:string>Italy</json:string><json:string>Louisville</json:string><json:string>Cali</json:string><json:string>Cleveland</json:string><json:string>Plymouth</json:string><json:string>Pretoria</json:string><json:string>Taipei</json:string><json:string>Spain</json:string><json:string>Delhi</json:string><json:string>Nanjing</json:string><json:string>Barnsley</json:string><json:string>New Haven</json:string><json:string>Lleida</json:string><json:string>Neurotoxicity</json:string><json:string>Lyon</json:string><json:string>Res Triangle Park</json:string><json:string>Belgium</json:string><json:string>Auckland City</json:string><json:string>San Jorge</json:string><json:string>Derbyshire</json:string><json:string>Netherlands</json:string><json:string>Osaka</json:string><json:string>Las Vegas</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Montanes-Rada et al</json:string><json:string>Univ Georgia, Clin Pharm Program, 1120</json:string><json:string>Albers et al</json:string><json:string>Toxicon Consortium Cook County, Sect Clin Toxicol, 1900</json:string><json:string>Genzyme Corp, 4545</json:string><json:string>ZymoGenetics Inc, 1201</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-SXHJF67B-7</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - pharmacology & pharmacy</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Pharmacology (medical)</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Epidemiology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2006</publicationDate><copyrightDate>2006</copyrightDate><doi><json:string>10.1002/pds.1178</json:string></doi><id>2BCF9D936A34E785E998F7ED585930ADCE5DC2FD</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-SXHJF67B-7/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-SXHJF67B-7/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-SXHJF67B-7/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Current awareness: Pharmacoepidemiology and drug safety</title><title level="a" type="short" xml:lang="en">Current Awareness</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><availability><licence>Copyright © 2006 John Wiley & Sons, Ltd.</licence></availability><date type="published" when="2006-05"></date></publicationStmt><notesStmt><note type="content-type" subtype="other" source="bibliography" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="other"><analytic><title level="a" type="main">Current awareness: Pharmacoepidemiology and drug safety</title><title level="a" type="short" xml:lang="en">Current Awareness</title><idno type="istex">2BCF9D936A34E785E998F7ED585930ADCE5DC2FD</idno><idno type="ark">ark:/67375/WNG-SXHJF67B-7</idno><idno type="DOI">10.1002/pds.1178</idno><idno type="unit">PDS1178</idno><idno type="toTypesetVersion">file:PDS.PDS1178.pdf</idno></analytic><monogr><title level="j" type="main">Pharmacoepidemiology and Drug Safety</title><title level="j" type="alt">PHARMACOEPIDEMIOLOGY AND DRUG SAFETY</title><idno type="pISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><idno type="book-DOI">10.1002/(ISSN)1099-1557</idno><idno type="book-part-DOI">10.1002/pds.v15:5</idno><idno type="product">PDS</idno><imprint><biblScope unit="vol">15</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="i">i</biblScope><biblScope unit="page" to="xii">xii</biblScope><biblScope unit="page-count">12</biblScope><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2006-05"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. </p></abstract><textClass><keywords rend="articleCategory"><term>Current Awareness</term></keywords><keywords rend="tocHeading1"><term>Current Awareness</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-SXHJF67B-7/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Ltd.</publisherName><publisherLoc>Chichester, UK</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1099-1557</doi><issn type="print">1053-8569</issn><issn type="electronic">1099-1557</issn><idGroup><id type="product" value="PDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="PHARMACOEPIDEMIOLOGY AND DRUG SAFETY">Pharmacoepidemiology and Drug Safety</title><title type="short">Pharmacoepidem. Drug Safe.</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/pds.v15:5</doi><numberingGroup><numbering type="journalVolume" number="15">15</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2006-05">May 2006</coverDate></publicationMeta><publicationMeta level="unit" type="bibliography" position="10" status="forIssue"><doi origin="wiley" registered="yes">10.1002/pds.1178</doi><idGroup><id type="unit" value="PDS1178"></id></idGroup><countGroup><count type="pageTotal" number="12"></count></countGroup><titleGroup><title type="articleCategory">Current Awareness</title><title type="tocHeading1">Current Awareness</title></titleGroup><copyright ownership="publisher">Copyright © 2006 John Wiley & Sons, Ltd.</copyright><eventGroup><event type="firstOnline" date="2006-05-02"></event><event type="publishedOnlineFinalForm" date="2006-05-02"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.12 mode:FullText source:FullText result:FullText" date="2010-07-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-06"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-03"></event></eventGroup><numberingGroup><numbering type="pageFirst">i</numbering><numbering type="pageLast">xii</numbering></numberingGroup><linkGroup><link type="toTypesetVersion" href="file:PDS.PDS1178.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="335"></count></countGroup><titleGroup><title type="main" xml:lang="en">Current awareness: Pharmacoepidemiology and drug safety</title><title type="short" xml:lang="en">Current Awareness</title></titleGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted. </p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Current awareness: Pharmacoepidemiology and drug safety</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Current Awareness</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Current awareness: Pharmacoepidemiology and drug safety</title></titleInfo><typeOfResource>text</typeOfResource><genre type="other" displayLabel="bibliography" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</genre><originInfo><publisher>John Wiley & Sons, Ltd.</publisher><place><placeTerm type="text">Chichester, UK</placeTerm></place><dateIssued encoding="w3cdtf">2006-05</dateIssued><copyrightDate encoding="w3cdtf">2006</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">0</extent><extent unit="tables">0</extent><extent unit="references">335</extent></physicalDescription><abstract lang="en">In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.</abstract><relatedItem type="host"><titleInfo><title>Pharmacoepidemiology and Drug Safety</title></titleInfo><titleInfo type="abbreviated"><title>Pharmacoepidem. Drug Safe.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Current Awareness</topic><topic>Current Awareness</topic></subject><identifier type="ISSN">1053-8569</identifier><identifier type="eISSN">1099-1557</identifier><identifier type="DOI">10.1002/(ISSN)1099-1557</identifier><identifier type="PublisherID">PDS</identifier><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>i</start><end>xii</end><total>12</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>1. Books, Reviews & Symposia</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Special issue: Bisphosphonates in metastatic bone disease: Renal safety matters</title></titleInfo><genre>journal-article</genre><note type="citation/reference">Special issue: Bisphosphonates in metastatic bone disease: Renal safety matters. Oncologist (2005); 10:</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail></part><relatedItem type="host"><titleInfo><title>Oncologist</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Special issue on drug‐induced torsades de pointes</title></titleInfo><genre>journal-article</genre><note type="citation/reference">Special issue on drug‐induced torsades de pointes. Heart Rhythm (2005); 2:</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>2</number></detail></part><relatedItem type="host"><titleInfo><title>Heart Rhythm</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>2</number></detail></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>International Society of Pharmacovigilance ‐ Abstracts ‐ 5th ISoP Annual Meeting ‐ ‘Pharmacovigilance ‐ A Global Concern: East meets West’ ‐ Manila, Philippines ‐ 17‐19 October, 2005</title></titleInfo><genre>journal-article</genre><note type="citation/reference">International Society of Pharmacovigilance ‐ Abstracts ‐ 5th ISoP Annual Meeting ‐ ‘Pharmacovigilance ‐ A Global Concern: East meets West’ ‐ Manila, Philippines ‐ 17‐19 October, 2005. Drug Saf (2005); 28: 929.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>929</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>929</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Benefit‐risk assessment of levetiracetam in the treatment of partial seizures</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Abou‐Khalil B. Benefit‐risk assessment of levetiracetam in the treatment of partial seizures. Drug Saf (2005); 28: 871.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>871</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>871</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Proposals for prevention and management of steroid‐induced osteoporosis in children and adolescents</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brown JJ, Zacharin MR. Proposals for prevention and management of steroid‐induced osteoporosis in children and adolescents. J Paediatr Child Health (2005); 41: 553.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>553</start></extent></part><relatedItem type="host"><titleInfo><title>J Paediatr Child Health</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>553</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Neurotoxicity induced by β‐lactam antibiotics: From bench to bedside</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by β‐lactam antibiotics: From bench to bedside. Eur J Clin Microbiol Infect Dis (2005); 24: 649.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>649</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Microbiol Infect Dis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>649</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Safety and tolerability of omalizumab (Xolair®), a recombinant humanized monoclonal anti‐IgE antibody</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Deniz VM, Gupta N. Safety and tolerability of omalizumab (Xolair®), a recombinant humanized monoclonal anti‐IgE antibody. Clin Rev Allergy Immunol (2005); 29: 31.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>31</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Rev Allergy Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>31</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Psychotropic drug‐induced neutropenia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Duggal HS, Singh I. Psychotropic drug‐induced neutropenia. Drugs Today (Barc) (2005); 41: 517.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>517</start></extent></part><relatedItem type="host"><titleInfo><title>Drugs Today (Barc)</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>517</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>A systematic review of the safety of analgesia with 50% nitrous oxide: Can lay responders use analgesic gases in the prehospital setting?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Faddy SC, Garlick SR. A systematic review of the safety of analgesia with 50% nitrous oxide: Can lay responders use analgesic gases in the prehospital setting?. Emerg Med J (2005); 22: 901.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>901</start></extent></part><relatedItem type="host"><titleInfo><title>Emerg Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>901</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Cardiotoxicity of cancer therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol (2005); 23: 7685.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>7685</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>7685</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Vaccine safety controversies and the future of vaccination programs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Francois G, Duclos P, Margolis H, Lavanchi D, Siegrist CA, Meheus A, Lambert PH, Emiroglu N, Badur S, Van Damme P. Vaccine safety controversies and the future of vaccination programs. Pediatr Infect Dis J (2005); 24: 953.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>953</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Infect Dis J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>953</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>The incidence of prescribing errors in hospital inpatients ‐ An overview of the research methods</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Franklin BD, Vincent C, Schachter M, Barber N. The incidence of prescribing errors in hospital inpatients ‐ An overview of the research methods. Drug Saf (2005); 28: 891.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>891</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>891</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Schizophrenia, antipsychotic drugs, and cardiovascular disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry (2005); 66: 5.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>5</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>5</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Drug‐drug interactions of antifungal agents and implications for patient care</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gubbins PO, Amsden JR. Drug‐drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother (2005); 6: 2231.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>2231</start></extent></part><relatedItem type="host"><titleInfo><title>Expert Opin Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>2231</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Antipsychotic poisoning in young children ‐ A systematic review</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Isibister GK, Balit CR, Kilham HA. Antipsychotic poisoning in young children ‐ A systematic review. Drug Saf (2005); 28: 1029.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>1029</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>1029</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Drug‐induced Q‐T prolongation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kao LW, Furbee RB. Drug‐induced Q‐T prolongation. Med Clin North Am (2005); 89: 1125.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>1125</start></extent></part><relatedItem type="host"><titleInfo><title>Med Clin North Am</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>1125</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Current status of nonsteroid anti‐inflammatory drugs in psychiatry ‐ Balancing risks and benefits in pain management</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kaplan RJ. Current status of nonsteroid anti‐inflammatory drugs in psychiatry ‐ Balancing risks and benefits in pain management. Am J Phys Med Rehabil (2005); 84: 885.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><extent unit="pages"><start>885</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Phys Med Rehabil</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>84</number></detail><extent unit="pages"><start>885</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Tolerability and safety of rituximab (MabThera®)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kimby E. Tolerability and safety of rituximab (MabThera®). Cancer Treat Rev (2005); 31: 456.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>456</start></extent></part><relatedItem type="host"><titleInfo><title>Cancer Treat Rev</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>456</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kulemann V, Bauer M, Graninger W, Joukhadar C. Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients. Pharmacology (2005); 75: 165.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>165</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>165</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Adverse effects of antiretroviral treatments (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lagrange‐Xelot M, Molina JM. Adverse effects of antiretroviral treatments (French, English Abstract). Presse Med (2005); 34: 1571.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>1571</start></extent></part><relatedItem type="host"><titleInfo><title>Presse Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>1571</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Toxicity‐sparing protocols using mycophenolate mofetil in renal transplantation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Land W, Vincenti F. Toxicity‐sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation (2005); 80: S221.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>S221</start></extent></part><relatedItem type="host"><titleInfo><title>Transplantation</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>S221</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Delirium associated with baclofen withdrawal: A review of common presentations and management strategies</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Leo RJ, Baer D. Delirium associated with baclofen withdrawal: A review of common presentations and management strategies. Psychosomatics (2005); 46: 503.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>503</start></extent></part><relatedItem type="host"><titleInfo><title>Psychosomatics</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>503</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>QTc interval prolongation and antipsychotic drug treatments: Focus on sertindole</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lindstrom E, Farde L, Eberhard J, Haverkamp W. QTc interval prolongation and antipsychotic drug treatments: Focus on sertindole. Int J Neuropsychopharmacol (2005); 8: 615.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>615</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Neuropsychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>615</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Antidepressants and seizures: Emphasis on newer agents and clinical implications</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Montgomery SA. Antidepressants and seizures: Emphasis on newer agents and clinical implications. Int J Clin Pract (2005); 59: 1435.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>1435</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Clin Pract</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>59</number></detail><extent unit="pages"><start>1435</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Drug‐induced weight gain</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ness‐Abramof R, Apovian CM. Drug‐induced weight gain. Drugs Today (Barc) (2005); 41: 547.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>547</start></extent></part><relatedItem type="host"><titleInfo><title>Drugs Today (Barc)</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>547</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>The clinical epidemiology of contrast‐induced nephropathy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Parfrey P. The clinical epidemiology of contrast‐induced nephropathy. Cardiovasc Intervent Radiol (2005); 28: S3.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>S3</start></extent></part><relatedItem type="host"><titleInfo><title>Cardiovasc Intervent Radiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>S3</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>Measurement of anticholinergic effects of psychotropic drugs in humans</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Penttila J, Scheinin H, Syvalahti E. Measurement of anticholinergic effects of psychotropic drugs in humans. Pharmacopsychiatry (2005); 38: 187.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>187</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacopsychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>187</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>Birth defects after prenatal exposure to antiepileptic drugs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol (2005); 4: 781.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>781</start></extent></part><relatedItem type="host"><titleInfo><title>Lancet Neurol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>781</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>Adverse effects of antiepileptic drugs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand (2005); 112: 30.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>30</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Neurol Scand</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>112</number></detail><extent unit="pages"><start>30</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>Drug‐induced acute kidney injury</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schetz M, Dasta J, Goldstein S, Golper T. Drug‐induced acute kidney injury. Curr Opin Crit Care (2005); 11: 555.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>555</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Crit Care</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>555</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>Risk management strategies in the postmarketing period ‐ Safety experience with the US and European bosentan surveillance programmes</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Segal ES, Valette C, Oster L, Bouley L, Edfjall C, Herrmann P, Raineri M, Kempff M, Beacham S, Van Lierop C. Risk management strategies in the postmarketing period ‐ Safety experience with the US and European bosentan surveillance programmes. Drug Saf (2005); 28: 971.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>971</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>971</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>Drugs, QTc interval prolongation and final ICH E14 guideline ‐ An important milestone with challenges ahead</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shah RR. Drugs, QTc interval prolongation and final ICH E14 guideline ‐ An important milestone with challenges ahead. Drug Saf (2005); 28: 1009.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>1009</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>1009</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX®) in pediatric and nonpediatric patients with bacterial conjunctivitis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Silver LH, Woodside AM, Montgomery DB. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX®) in pediatric and nonpediatric patients with bacterial conjunctivitis. Surv Ophthalmol (2005); 50: S55.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>S55</start></extent></part><relatedItem type="host"><titleInfo><title>Surv Ophthalmol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>S55</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>Reducing the risks for contrast‐induced nephropathy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stacul F. Reducing the risks for contrast‐induced nephropathy. Cardiovasc Intervent Radiol (2005); 28: S12.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>S12</start></extent></part><relatedItem type="host"><titleInfo><title>Cardiovasc Intervent Radiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>S12</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>Antipsychotic drugs and QT prolongation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol (2005); 20: 243.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>243</start></extent></part><relatedItem type="host"><titleInfo><title>Int Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>243</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>Strategies for managing antidepressant‐induced sexual dysfunction: Systematic review of randomised controlled trials</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Taylor MJ, Rudkin L, Hawton K. Strategies for managing antidepressant‐induced sexual dysfunction: Systematic review of randomised controlled trials. J Affect Disord (2005); 88: 241.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>241</start></extent></part><relatedItem type="host"><titleInfo><title>J Affect Disord</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>241</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>Antirheumatic drugs in pregnancy and lactation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum (2005); 35: 112.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>112</start></extent></part><relatedItem type="host"><titleInfo><title>Semin Arthritis Rheum</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>112</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>Ocular toxicity due to chloroquine and hydroxychloroquine: Electrophysiological and visual function correlates</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tzekov R. Ocular toxicity due to chloroquine and hydroxychloroquine: Electrophysiological and visual function correlates. Doc Ophthalmol (2005); 110: 111.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>111</start></extent></part><relatedItem type="host"><titleInfo><title>Doc Ophthalmol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>111</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit40"><titleInfo><title>Antipsychotics for behavioural and psychological problems in elderly people with dementia ‐ A systematic review of adverse events</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van Iersel MB, Zuidema SU, Koopmans RTCM, Verhey FRJ, Rikkert MGMO. Antipsychotics for behavioural and psychological problems in elderly people with dementia ‐ A systematic review of adverse events. Drugs Aging (2005); 22: 845.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>845</start></extent></part><relatedItem type="host"><titleInfo><title>Drugs Aging</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>845</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit41"><titleInfo><title>Safety of statins: Effects on muscle and the liver</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vasudevan AR, Hamirani YS, Jones PH. Safety of statins: Effects on muscle and the liver. Cleve Clin J Med (2005); 72: 990.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>990</start></extent></part><relatedItem type="host"><titleInfo><title>Cleve Clin J Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>72</number></detail><extent unit="pages"><start>990</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit42"><titleInfo><title>Osteoporosis due to glucocorticoid use in children with chronic illness</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ward LM. Osteoporosis due to glucocorticoid use in children with chronic illness. Horm Res (2005); 64: 209.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>209</start></extent></part><relatedItem type="host"><titleInfo><title>Horm Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>209</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit43"><titleInfo><title>Drug‐ and toxin‐associated seizures</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wills B, Erickson T. Drug‐ and toxin‐associated seizures. Med Clin North Am (2005); 89: 1297.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>1297</start></extent></part><relatedItem type="host"><titleInfo><title>Med Clin North Am</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>1297</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit44"><titleInfo><title>2. General</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit45"><titleInfo><title>Perspectives on the use of data mining in pharmacovigilance</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Almenoff J, Tonning JM, Gould AL, Szarfman A, Hauben M, Ouellet‐Hellstrom R, Ball R, Hornbuckle K, Walsh L, Yee C, Sacks ST, Yuen N, Patadia V, Blum M, Johnston M, Gerrits C, Seifert H, Lacroix K. Perspectives on the use of data mining in pharmacovigilance. Drug Saf (2005); 28: 981.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>981</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>981</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit46"><titleInfo><title>Clarification of terminology in drug safety</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf (2005); 28: 851.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>851</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>851</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit47"><titleInfo><title>Medication use and risk of non‐Hodgkin's lymphoma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chang ET, Smedby KE, Hjalgrim H, Schollkopf C, Porwit‐MacDonald A, Sundstrom C, Tani E, d'Amore F, Melbye M, Adami HO, Glimelius B. Medication use and risk of non‐Hodgkin's lymphoma. Am J Epidemiol (2005); 162: 965.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>162</number></detail><extent unit="pages"><start>965</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Epidemiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>162</number></detail><extent unit="pages"><start>965</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit48"><titleInfo><title>Nephrotoxic drugs (German)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Czock D, Haussler U, Aymanns C, Keller F. Nephrotoxic drugs (German). Dtsch Med Wochenschr (2005); 130: 2579.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>130</number></detail><extent unit="pages"><start>2579</start></extent></part><relatedItem type="host"><titleInfo><title>Dtsch Med Wochenschr</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>130</number></detail><extent unit="pages"><start>2579</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit49"><titleInfo><title>Drug‐drug interactions among recently hospitalised patients ‐ Frequent but mostly clinically insignificant</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Glintborg B, Andersen SE, Dalhoff K. Drug‐drug interactions among recently hospitalised patients ‐ Frequent but mostly clinically insignificant. Eur J Clin Pharmacol (2005); 61: 675.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>675</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Clin Pharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>675</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit50"><titleInfo><title>Data mining in pharmacovigilance ‐ The need for a balanced perspective</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hauben M, Patadia V, Gerrits C, Walsh L, Reich L. Data mining in pharmacovigilance ‐ The need for a balanced perspective. Drug Saf (2005); 28: 835.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>835</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>835</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit51"><titleInfo><title>Testing and implementing signal impact analysis in a regulatory setting ‐ Results of a pilot study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Heeley E, Waller P, Moseley J. Testing and implementing signal impact analysis in a regulatory setting ‐ Results of a pilot study. Drug Saf (2005); 28: 901.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>901</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>901</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit52"><titleInfo><title>A case of drug‐induced hypersensitivity syndrome with multiple organ involvement treated with plasma exchange</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Higuchi M, Agatsuma T, Iizima M, Yamazaki Y, Saita T, Ichikawa T, Kamijo Y, Arakura H, Hora K, Kiyosawa K. A case of drug‐induced hypersensitivity syndrome with multiple organ involvement treated with plasma exchange. Ther Apher Dial (2005); 9: 412.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>412</start></extent></part><relatedItem type="host"><titleInfo><title>Ther Apher Dial</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>412</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit53"><titleInfo><title>Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kane‐Gill SL, Kirisci L, Pathak DS. Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit?. Ann Pharmacother (2005); 39: 1823.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1823</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1823</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit54"><titleInfo><title>Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vallano A, Cereza G, Pedros C, Agusti A, Danes I, Aguilera C, Arnau JM. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol (2005); 60: 653.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>653</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>653</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit55"><titleInfo><title>Impact analysis of signals detected from spontaneous adverse drug reaction reporting data</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Waller P, Heeley E, Moseley J. Impact analysis of signals detected from spontaneous adverse drug reaction reporting data. Drug Saf (2005); 28: 843.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>843</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>843</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit56"><titleInfo><title>Detecting treatment emergent adverse events in clinical trials ‐ A comparison of spontaneously reported and solicited collection methods</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wernicke JF, Faries D, Milton D, Weyrauch K. Detecting treatment emergent adverse events in clinical trials ‐ A comparison of spontaneously reported and solicited collection methods. Drug Saf (2005); 28: 1057.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>1057</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>1057</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit57"><titleInfo><title>3. Anti‐infective Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit58"><titleInfo><title>Community‐Acquired Pneumonia Recovery in the Elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH. Community‐Acquired Pneumonia Recovery in the Elderly (CAPRIE): Efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis (2006); 42: 73.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>73</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Infect Dis</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>73</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit59"><titleInfo><title>Rifampin induced arthritis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Azap OK, Arslan H, Timurkaynak F. Rifampin induced arthritis (Letter). J Infect (2005); 51: 261.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>261</start></extent></part><relatedItem type="host"><titleInfo><title>J Infect</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>261</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit60"><titleInfo><title>Hypoglycemia associated with the use of gatifloxacin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bhasin R, Arce FC, Pasmantier R. Hypoglycemia associated with the use of gatifloxacin. Am J Med Sci (2005); 330: 250.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>250</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Med Sci</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>250</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit61"><titleInfo><title>Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: Case report and review of the literature</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bickford CL, Spencer AP. Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: Case report and review of the literature. Pharmacotherapy (2005); 25: 1389.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1389</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1389</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit62"><titleInfo><title>Long‐term antiretroviral efficacy and safety of lopinavir/ritonavir in HAART‐experienced subjects: 4 year follow‐up 1934 study (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bongiovanni M, Bini T, Capetti A, Trovati S, Di Biagio A, Tordato F, Monforte AD. Long‐term antiretroviral efficacy and safety of lopinavir/ritonavir in HAART‐experienced subjects: 4 year follow‐up 1934 study (Letter). AIDS (2005); 19: 1934.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>1934</start></extent></part><relatedItem type="host"><titleInfo><title>AIDS</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>1934</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit63"><titleInfo><title>Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double‐blind phase 3 comparison study with vancomycin‐aztreonam</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, Gioud‐Paquet M, Dartois N, Ellis‐Grosse EJ, Loh E. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double‐blind phase 3 comparison study with vancomycin‐aztreonam. Antimicrob Agents Chemother (2005); 49: 4658.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>4658</start></extent></part><relatedItem type="host"><titleInfo><title>Antimicrob Agents Chemother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>4658</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit64"><titleInfo><title>Antiretroviral therapy and the prevalence and incidence of diabetes (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brown TT, Cole SR, Li XH. Antiretroviral therapy and the prevalence and incidence of diabetes (Reply). Arch Intern Med (2005); 165: 2537.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>2537</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Intern Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>2537</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit65"><titleInfo><title>Acute renal failure and severe neurotoxicity following valacyclovir (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carlon R, Possamai C, Corbanese U. Acute renal failure and severe neurotoxicity following valacyclovir (Letter). Intensive Care Med (2005); 31: 1593.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>1593</start></extent></part><relatedItem type="host"><titleInfo><title>Intensive Care Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>1593</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit66"><titleInfo><title>Adverse events associated with smallpox vaccination in the United States, January‐October 2003</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Casey CG, Iskander JK, Roper MH, Mast EE, Wen XJ, Torok TJ, Chapman LE, Swerdlow DL, Morgan J, Heffelfinger JD, Vitek C, Reef SE, Hasbrouck LM, Damon I, Neff L, Vellozzi C, McCauley M, Strikas RA, Mootrey G. Adverse events associated with smallpox vaccination in the United States, January‐October 2003. JAMA (2005); 294: 2734.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2734</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2734</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit67"><titleInfo><title>Hepatitis B vaccination and multiple sclerosis (Editorial) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Confavreux C. Hepatitis B vaccination and multiple sclerosis (Editorial) (French). Presse Med (2005); 34: 1205.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>1205</start></extent></part><relatedItem type="host"><titleInfo><title>Presse Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>1205</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit68"><titleInfo><title>Allergic contact dermatitis to naftifine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Corazza M, Lauriola MM, Virgili A. Allergic contact dermatitis to naftifine. Contact Dermatitis (2005); 53: 302.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>302</start></extent></part><relatedItem type="host"><titleInfo><title>Contact Dermatitis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>302</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit69"><titleInfo><title>Linezolid‐induced dyserythropoiesis: Chloramphenicol toxicity revisited</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dawson MA, Davis A, Elliott P, Cole‐Sinclair M. Linezolid‐induced dyserythropoiesis: Chloramphenicol toxicity revisited. Intern Med J (2005); 35: 626.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>626</start></extent></part><relatedItem type="host"><titleInfo><title>Intern Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>626</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit70"><titleInfo><title>Neuropsychiatric effects of efavirenz: Delayed onset (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dawson S, Woods C. Neuropsychiatric effects of efavirenz: Delayed onset (Letter). Int J STD AIDS (2005); 16: 769.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>769</start></extent></part><relatedItem type="host"><titleInfo><title>Int J STD AIDS</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>769</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit71"><titleInfo><title>Safety and pharmacokinetics of coadministered voriconazole and anidulafungin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol (2005); 45: 1373.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1373</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Pharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1373</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit72"><titleInfo><title>Terbinafine‐induced subacute cutaneous lupus erythematosus</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Farhi D, Viguier M, Cosnes A, Reygagne P, Dubertret L, Revuz J, Roujeau JC, Bachelez H. Terbinafine‐induced subacute cutaneous lupus erythematosus. Dermatology (2006); 212: 59.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>212</number></detail><extent unit="pages"><start>59</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatology</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>212</number></detail><extent unit="pages"><start>59</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit73"><titleInfo><title>Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fontaine C, Guiard‐Schmid JB, Slama L, Essid A, Lukiana T, Rondeau E, Pialoux G. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate (Letter). AIDS (2005); 19: 1927.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>1927</start></extent></part><relatedItem type="host"><titleInfo><title>AIDS</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>1927</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit74"><titleInfo><title>Transient bulging fontanelle after vaccination: Case report and review of the vaccine adverse event reporting system</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Freedman SB, Reed J, Burwen DR, Wise RP, Weiss A, Ball R. Transient bulging fontanelle after vaccination: Case report and review of the vaccine adverse event reporting system. J Pediatr (2005); 147: 640.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>147</number></detail><extent unit="pages"><start>640</start></extent></part><relatedItem type="host"><titleInfo><title>J Pediatr</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>147</number></detail><extent unit="pages"><start>640</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit75"><titleInfo><title>Nitrofurantoin associated parotiditis (Letter) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gervilla‐Cano J, Otal‐Bareche J, Torres‐Justribo M, Duran‐Rabes J. Nitrofurantoin associated parotiditis (Letter) (Spanish). Med Clin (Barc) (2005); 125: 519.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>519</start></extent></part><relatedItem type="host"><titleInfo><title>Med Clin (Barc)</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>519</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit76"><titleInfo><title>Interferon α‐2b in combination with ribavirin for the treatment of chronic hepatitis C in children: Efficacy, safety, and pharmacokinetics</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gonzalez‐Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli‐Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M. Interferon α‐2b in combination with ribavirin for the treatment of chronic hepatitis C in children: Efficacy, safety, and pharmacokinetics. Hepatology (2005); 42: 1010.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1010</start></extent></part><relatedItem type="host"><titleInfo><title>Hepatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1010</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit77"><titleInfo><title>Fixed drug eruption caused by ornidazole</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gupta S, Jain VK, Aggarwal K, Gupta S, Mahendra A. Fixed drug eruption caused by ornidazole. Contact Dermatitis (2005); 53: 300.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>300</start></extent></part><relatedItem type="host"><titleInfo><title>Contact Dermatitis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>300</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit78"><titleInfo><title>Prediction of neuropsychiatric adverse events associated with long‐term efavirenz therapy, using plasma drug level monitoring</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gutierrez F, Navarro A, Padilla S, Anton R, Masia M, Borras J, Martin‐Hidalgo A. Prediction of neuropsychiatric adverse events associated with long‐term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis (2005); 41: 1648.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1648</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Infect Dis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1648</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit79"><titleInfo><title>Safety and elicitation of humoral and cellular responses in Colombian malaria‐naive volunteers by a Plasmodium vivax circumsporozoite protein‐derived synthetic vaccine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Herrera S, Bonelo A, Perlaza BL, Fernandez OL, Victoria L, Lenis AM, Soto L, Hurtado H, Acuna LM, Velez JD, Palacios R, Chen‐ Mok M, Corradin G, Arevalo‐Herrera M. Safety and elicitation of humoral and cellular responses in Colombian malaria‐naive volunteers by a Plasmodium vivax circumsporozoite protein‐derived synthetic vaccine. Am J Trop Med Hyg (2005); 73: 3.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>3</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Trop Med Hyg</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>3</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit80"><titleInfo><title>Characterization of M gene‐deficient rabies virus with advantages of effective immunization and safety as a vaccine strain</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ito N, Sugiyama M, Yamada K, Shimizu K, Takayama‐Ito M, Hosokawa J, Minamoto N. Characterization of M gene‐deficient rabies virus with advantages of effective immunization and safety as a vaccine strain. Microbiol Immunol (2005); 49: 973.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>973</start></extent></part><relatedItem type="host"><titleInfo><title>Microbiol Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>973</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit81"><titleInfo><title>Evolution of a rare vaccine‐derived multirecombinant poliovirus</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Karakasiliotis I, Paximadi E, Markoulatos P. Evolution of a rare vaccine‐derived multirecombinant poliovirus. J Gen Virol (2005); 86: 3137.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>86</number></detail><extent unit="pages"><start>3137</start></extent></part><relatedItem type="host"><titleInfo><title>J Gen Virol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>86</number></detail><extent unit="pages"><start>3137</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit82"><titleInfo><title>Injection site with generalized rash caused by pegylated interferon α 2a injection</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kawada K, Maeda N, Kobayashi S, Sowa J, Tsuruta D, Kawada N. Injection site with generalized rash caused by pegylated interferon α 2a injection. Dermatology (2006); 212: 82.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>212</number></detail><extent unit="pages"><start>82</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatology</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>212</number></detail><extent unit="pages"><start>82</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit83"><titleInfo><title>Linezolid induced toxic optic neuropathy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kulkarni K, Del Priore LV, Kulkarni K. Linezolid induced toxic optic neuropathy (Letter). Br J Ophthalmol (2005); 89: 1664.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>1664</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Ophthalmol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>1664</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit84"><titleInfo><title>Antiretroviral treatments‐related lipodystrophy syndrome: Clinico‐pathological findings (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lassalle S, Cervera P, Hofman V, Mari M, Dellamonica P, Hofman P. Antiretroviral treatments‐related lipodystrophy syndrome: Clinico‐pathological findings (French, English Abstract). Ann Pathol (2005); 25: 309.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>309</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pathol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>309</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit85"><titleInfo><title>Antiretroviral therapy and the prevalence and incidence of diabetes (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mikhail N, Cope D. Antiretroviral therapy and the prevalence and incidence of diabetes (Letter). Arch Intern Med (2005); 165: 2536.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>2536</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Intern Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>2536</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit86"><titleInfo><title>Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E, Reiss P, Katlama C, Phillips AN, Lundgren JD. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?. Antivir Ther (2005); 10: 779.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>779</start></extent></part><relatedItem type="host"><titleInfo><title>Antivir Ther</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>779</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit87"><titleInfo><title>A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community‐acquired pneumonia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Morganroth J, DiMarco JP, Anzueto A, Niederman MS, Choudhri SJ. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community‐acquired pneumonia. Chest (2005); 128: 3398.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>128</number></detail><extent unit="pages"><start>3398</start></extent></part><relatedItem type="host"><titleInfo><title>Chest</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>128</number></detail><extent unit="pages"><start>3398</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit88"><titleInfo><title>Interaction of ritonavir‐boosted tipranavir with loperamide does not result in loperamide‐associated neurologic side effects in healthy volunteers</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mukwaya G, MacGregor T, Hoelscher D, Heming T, Legg D, Kavanaugh K, Johnson P, Sabo JP, McCallister S. Interaction of ritonavir‐boosted tipranavir with loperamide does not result in loperamide‐associated neurologic side effects in healthy volunteers. Antimicrob Agents Chemother (2005); 49: 4903.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>4903</start></extent></part><relatedItem type="host"><titleInfo><title>Antimicrob Agents Chemother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>4903</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit89"><titleInfo><title>Vaccine safety ‐ Achieving the proper balance (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Neuzil KM, Griffin MR. Vaccine safety ‐ Achieving the proper balance (Editorial). JAMA (2005); 294: 2763.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2763</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2763</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit90"><titleInfo><title>Rifabutin‐associated uveitis in a child</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Olesen HH, Krag S. Rifabutin‐associated uveitis in a child. Pediatr Infect Dis J (2005); 24: 1023.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>1023</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Infect Dis J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>1023</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit91"><titleInfo><title>Fluoroquinolone‐associated dysglycemias: A tale of two toxicities</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Owens RC. Fluoroquinolone‐associated dysglycemias: A tale of two toxicities. Pharmacotherapy (2005); 25: 1291.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1291</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1291</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit92"><titleInfo><title>Retransplantation for acute liver failure due to combined antiviral agents in an HIV‐HCV coinfected liver transplant recipient (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Polard E, Camus C, Abault AY, Turlin B, Arvieux U, Messner M, Allain H, Boudjema K. Retransplantation for acute liver failure due to combined antiviral agents in an HIV‐HCV coinfected liver transplant recipient (Letter). Transplantation (2005); 80: 1136.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>1136</start></extent></part><relatedItem type="host"><titleInfo><title>Transplantation</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>1136</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit93"><titleInfo><title>Selective immediate hypersensitivity to cefodizime</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Romano A, Viola M, Gueant‐Rodriguez RM, Valluzzi RL, Gueant JL. Selective immediate hypersensitivity to cefodizime. Allergy (2005); 60: 1545.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1545</start></extent></part><relatedItem type="host"><titleInfo><title>Allergy</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1545</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit94"><titleInfo><title>Neurologic adverse events associated with smallpox vaccination in the United States, 2002‐2004</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sejvar JJ, Labutta RJ, Chapman LE, Grabenstein JD, Iskander J, Lane JM. Neurologic adverse events associated with smallpox vaccination in the United States, 2002‐2004. JAMA (2005); 294: 2744.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2744</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2744</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit95"><titleInfo><title>Major depressive episode with psychotic features induced by pegylated interferon‐α‐2b and ribavirin treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sockalingam S, Balderson K. Major depressive episode with psychotic features induced by pegylated interferon‐α‐2b and ribavirin treatment. Int Clin Psychopharmacol (2005); 20: 289.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>289</start></extent></part><relatedItem type="host"><titleInfo><title>Int Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>289</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit96"><titleInfo><title>Mitochondrial toxicity associated with linezolid (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid (Letter). N Engl J Med (2005); 353: 2305.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2305</start></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2305</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit97"><titleInfo><title>Development of diabetes after gatifloxacin therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stading JA, Chock AWY, Skrabal MZ, Faulkner MA. Development of diabetes after gatifloxacin therapy. Am J Health Syst Pharm (2005); 62: 2293.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>2293</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Health Syst Pharm</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>2293</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit98"><titleInfo><title>Splinter haemorrhages associated with oral terbinafine in a Chinese man (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tan C, Zhu WY. Splinter haemorrhages associated with oral terbinafine in a Chinese man (Letter). Clin Exp Dermatol (2006); 31: 153.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>153</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Dermatol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>153</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit99"><titleInfo><title>Short‐term safety and pharmacodynamics of amdoxovir in HIV‐infected patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Thompson MA, Kessler HA, Eron JJ, Jacobson JM, Adda N, Shen G, Zong J, Harris J, Moxham C, Rousseau FS. Short‐term safety and pharmacodynamics of amdoxovir in HIV‐infected patients. AIDS (2005); 19: 1607.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>1607</start></extent></part><relatedItem type="host"><titleInfo><title>AIDS</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>1607</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit100"><titleInfo><title>Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tremolieres F. Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults (French, English Abstract). Pathol Biol (2005); 53: 503.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>503</start></extent></part><relatedItem type="host"><titleInfo><title>Pathol Biol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>503</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit101"><titleInfo><title>Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment‐experienced HIV‐1 infected adults over 48 weeks</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arasteh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ, Cohen C, Kinchelow T, Bertasso A, Labriola‐Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader‐Weder S, Demasi R, Smiley L, Salgo MP. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment‐experienced HIV‐1 infected adults over 48 weeks. J Acquir Immune Defic Syndr Hum Retrovirol (2005); 40: 413.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>413</start></extent></part><relatedItem type="host"><titleInfo><title>J Acquir Immune Defic Syndr Hum Retrovirol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>413</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit102"><titleInfo><title>Sulfadiazine‐induced methemoglobinemia in a boy with thalassemia (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsai TC, Peng SK, Shih YR, Luk HN. Sulfadiazine‐induced methemoglobinemia in a boy with thalassemia (Letter). Can J Anaesth (2005); 52: 1002.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>1002</start></extent></part><relatedItem type="host"><titleInfo><title>Can J Anaesth</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>1002</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit103"><titleInfo><title>Mitochondrial hepatic toxicity associated with antiretroviral treatment (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van Huyen JPD, Batisse D, Belair MF, Bruneval P. Mitochondrial hepatic toxicity associated with antiretroviral treatment (French, English Abstract). Ann Pathol (2005); 25: 299.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>299</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pathol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>299</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit104"><titleInfo><title>Vaccine adverse event reporting: The importance of follow‐up (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Varricchio F. Vaccine adverse event reporting: The importance of follow‐up (Editorial). Expert Rev Vaccines (2005); 4: 445.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>445</start></extent></part><relatedItem type="host"><titleInfo><title>Expert Rev Vaccines</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>445</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit105"><titleInfo><title>Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother (2005); 49: 4536.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>4536</start></extent></part><relatedItem type="host"><titleInfo><title>Antimicrob Agents Chemother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>4536</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit106"><titleInfo><title>Association analysis of drug metabolizing enzyme gene polymorphisms in AIDS patients with cutaneous reactions to sulfonamides (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wolkenstein P, Loriot MA, Flahault A, Cadilhac M, Caumes E, Eliaszewicz M, Beaune P, Roujeau JC, Chosidow O. Association analysis of drug metabolizing enzyme gene polymorphisms in AIDS patients with cutaneous reactions to sulfonamides (Letter). J Investig Dermatol (2005); 125: 1080.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>1080</start></extent></part><relatedItem type="host"><titleInfo><title>J Investig Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>1080</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit107"><titleInfo><title>4. Cardiovascular System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit108"><titleInfo><title>Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery ‐ PREVENT IV: A randomized controlled trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Alexander JH, Hafley G, Harrington R, Peterson ED, Ferguson TB, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery ‐ PREVENT IV: A randomized controlled trial. JAMA (2005); 294: 2446.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2446</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2446</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit109"><titleInfo><title>Pulmonary toxicity of amiodarone (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bonniaud R. Pulmonary toxicity of amiodarone (French). Rev Mal Respir (2005); 22: S124.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>S124</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Mal Respir</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>S124</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit110"><titleInfo><title>Comparison of efficacy and safety assessment of fluvastatin in patients <65 years versus >/=65 years of age</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bruckert E, Verpilleux MP, Dejager S, Isaacsohn J. Comparison of efficacy and safety assessment of fluvastatin in patients <65 years versus >/=65 years of age. Am J Cardiol (2005); 96: 1142.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>1142</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>1142</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit111"><titleInfo><title>Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">D'Aloia A, Faggiano P, Brentana L, Boldini A, Pedrinazzi C, Procopio R, Dei Cas L. Sustained torsade de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease (Letter). Int J Cardiol (2005); 105: 337.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>105</number></detail><extent unit="pages"><start>337</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>105</number></detail><extent unit="pages"><start>337</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit112"><titleInfo><title>Eosinophilic fasciitis secondary to treatment with atorvastatin (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">DeGiovanni C, Chard M, Woollons A. Eosinophilic fasciitis secondary to treatment with atorvastatin (Letter). Clin Exp Dermatol (2006); 31: 131.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>131</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Dermatol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>131</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit113"><titleInfo><title>Perioperative β‐blocker therapy and mortality (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dunn PF, Landesberg G. Perioperative β‐blocker therapy and mortality (Letter). N Engl J Med (2005); 353: 2514.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2514</start></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2514</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit114"><titleInfo><title>Periocular cutaneous pigmentary changes associated with bimatoprost use</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Galloway GD, Eke T, Broadway DC. Periocular cutaneous pigmentary changes associated with bimatoprost use. Arch Ophthalmol (2005); 123: 1609.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>1609</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Ophthalmol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>1609</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit115"><titleInfo><title>Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gomberg‐Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol (2005); 96: 1334.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>1334</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>1334</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit116"><titleInfo><title>Myoclonus and angiotensin converting enzyme inhibitors (Letter) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gonzalez L, Feijoo M. Myoclonus and angiotensin converting enzyme inhibitors (Letter) (Spanish). Med Clin (Barc) (2005); 125: 398.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>398</start></extent></part><relatedItem type="host"><titleInfo><title>Med Clin (Barc)</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>398</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit117"><titleInfo><title>Safety and efficacy of atorvastatin in patients with severe renal dysfunction</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Holmberg B, Brannstrom M, Bucht B, Crougneau V, Dimeny E, Ekspong A, Granroth B, Grontoft KC, Hadimeri H, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L, Mikaelsson L, Olausson E, Persson B, Welin D, Wikdahl AM, Stegmayr BG. Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scand J Urol Nephrol (2005); 39: 503.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>503</start></extent></part><relatedItem type="host"><titleInfo><title>Scand J Urol Nephrol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>503</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit118"><titleInfo><title>A randomized, double‐blind, placebo‐controlled study of the safety and efficacy of intravenous MCC‐135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Rationale and design of the Evaluation of MCC‐135 for Left Ventricular Salvage in Acute MI (EVOLVE) study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jang IK, Pettigrew V, Picard MH, Kowey PR, Demmel V, Zile MR, Tatsuno J, Wackers FJT, Hibberd M. A randomized, double‐blind, placebo‐controlled study of the safety and efficacy of intravenous MCC‐135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Rationale and design of the Evaluation of MCC‐135 for Left Ventricular Salvage in Acute MI (EVOLVE) study. J Thromb Thrombolysis (2005); 20: 147.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>147</start></extent></part><relatedItem type="host"><titleInfo><title>J Thromb Thrombolysis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>147</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit119"><titleInfo><title>Bimatoprost‐induced periocular skin hyperpigmentation ‐ Histopathological study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kapur R, Osmanovic S, Toyran S, Edward DP. Bimatoprost‐induced periocular skin hyperpigmentation ‐ Histopathological study. Arch Ophthalmol (2005); 123: 1541.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>1541</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Ophthalmol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>1541</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit120"><titleInfo><title>Severe ataxia caused by amiodarone</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Krauser DG, Segal AZ, Kligfield P. Severe ataxia caused by amiodarone. Am J Cardiol (2005); 96: 1463.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>1463</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>1463</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit121"><titleInfo><title>A case of rhabdomyolysis induced acute renal failure secondary to statin‐fibrate‐derivative combination and occult hypothyroidism</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kursat S, Alici T, Colak HB. A case of rhabdomyolysis induced acute renal failure secondary to statin‐fibrate‐derivative combination and occult hypothyroidism. Clin Nephrol (2005); 64: 391.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>391</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Nephrol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>391</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit122"><titleInfo><title>Perioperative β‐blocker therapy and mortality (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lindenauer PK, Pekow P, Benjamin EM. Perioperative β‐blocker therapy and mortality (Reply). N Engl J Med (2005); 353: 2514.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2514</start></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2514</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit123"><titleInfo><title>Hepatic cirrhosis caused by low‐dose oral amiodarone therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Puli SR, Fraley MA, Puli V, Kuperman AB, Alpert MA. Hepatic cirrhosis caused by low‐dose oral amiodarone therapy. Am J Med Sci (2005); 330: 257.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>257</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Med Sci</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>330</number></detail><extent unit="pages"><start>257</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit124"><titleInfo><title>Safety of dobutamine contrast stress echocardiography (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Timperley L, Becher H. Safety of dobutamine contrast stress echocardiography (Letter). J Am Coll Cardiol (2005); 46: 1963.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1963</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Coll Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1963</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit125"><titleInfo><title>Perioperative β‐blocker therapy and mortality (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tran HA, Tran PH. Perioperative β‐blocker therapy and mortality (Letter). N Engl J Med (2005); 353: 2514.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2514</start></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2514</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit126"><titleInfo><title>Safety of dobutamine contrast stress echocardiography (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsutsui JM, Elhendy A, Xie F, O'Leary E, McGrain AC, Porter TR. Safety of dobutamine contrast stress echocardiography (Reply). J Am Coll Cardiol (2005); 46: 1963.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1963</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Coll Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1963</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit127"><titleInfo><title>Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med (2005); 2: 856.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>856</start></extent></part><relatedItem type="host"><titleInfo><title>J Sex Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>856</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit128"><titleInfo><title>Perioperative β‐blocker therapy and mortality (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vandenbunder B, Mignon A. Perioperative β‐blocker therapy and mortality (Letter). N Engl J Med (2005); 353: 2513.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2513</start></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2513</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit129"><titleInfo><title>Efficacy and safety of fasudil in patients with stable angina ‐ A double‐blind, placebo‐controlled, phase 2 trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vicari RM, Chaitman B, Keefe D, Smith WB, Chrysant SG, Tonkon MJ, Bittar N, Weiss RJ, Morales‐Ballejo H, Thadani U. Efficacy and safety of fasudil in patients with stable angina ‐ A double‐blind, placebo‐controlled, phase 2 trial. J Am Coll Cardiol (2005); 46: 1803.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1803</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Coll Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1803</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit130"><titleInfo><title>5. CNS Depressive Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit131"><titleInfo><title>The efficacy and side effects of topiramate on refractory epilepsy in infants and young children: A multi‐center clinical trial</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Al Ajlouni S, Shorman A, Daoud AS. The efficacy and side effects of topiramate on refractory epilepsy in infants and young children: A multi‐center clinical trial. Seizure (2005); 14: 459.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>459</start></extent></part><relatedItem type="host"><titleInfo><title>Seizure</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>459</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit132"><titleInfo><title>Severe case of phenytoin‐induced anticonvulsant hypersensitivity syndrome</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Amato A, Marlowe KF. Severe case of phenytoin‐induced anticonvulsant hypersensitivity syndrome. Am J Health Syst Pharm (2005); 62: 2295.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>2295</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Health Syst Pharm</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>2295</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit133"><titleInfo><title>Epilepsy and medication effects on the pattern visual evoked potential</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Geller AM, Hudnell HK, Vaughn BV, Messenheimer JA, Boyes WK. Epilepsy and medication effects on the pattern visual evoked potential. Doc Ophthalmol (2005); 110: 121.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>121</start></extent></part><relatedItem type="host"><titleInfo><title>Doc Ophthalmol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>121</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit134"><titleInfo><title>Improvement of oligoasthenozoospermia in epileptic patients on switching anti‐epilepsy medication from sodium valproate to phenytoin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hayashi T, Yoshida S, Yoshinaga A, Ohno R, Ishii N, Yamada T. Improvement of oligoasthenozoospermia in epileptic patients on switching anti‐epilepsy medication from sodium valproate to phenytoin. Scand J Urol Nephrol (2005); 39: 431.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>431</start></extent></part><relatedItem type="host"><titleInfo><title>Scand J Urol Nephrol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>431</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit135"><titleInfo><title>Decrease of folic acid and cognitive alterations in patients with epilepsy treated with phenytoin or carmabazepine, pilot study (Spanish, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hernandez R, Fernandez MDA, Miranda G, Suastegui R. Decrease of folic acid and cognitive alterations in patients with epilepsy treated with phenytoin or carmabazepine, pilot study (Spanish, English Abstract). Rev Invest Clin (2005); 57: 522.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>522</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Invest Clin</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>522</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit136"><titleInfo><title>Propofol‐induced seizure‐like phenomena</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hickey KS, Martin DF, Chuidian FX. Propofol‐induced seizure‐like phenomena. J Emerg Med (2005); 29: 447.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>447</start></extent></part><relatedItem type="host"><titleInfo><title>J Emerg Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>447</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit137"><titleInfo><title>Carbamazepine‐induced hyponatremia: Assessment of risk factors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kuz GM, Manssourian A. Carbamazepine‐induced hyponatremia: Assessment of risk factors. Ann Pharmacother (2005); 39: 1943.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1943</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1943</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit138"><titleInfo><title>Avoidable adverse event: Carbamazepine encephalopathy when introducing clarithromycine (Letter) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Leclercq V, Lacaille S, Delpierre S, Karoubi E, Legram S. Avoidable adverse event: Carbamazepine encephalopathy when introducing clarithromycine (Letter) (French). Rev Med Interne (2005); 26: 835.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>835</start></extent></part><relatedItem type="host"><titleInfo><title>Rev Med Interne</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>835</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit139"><titleInfo><title>Visual defects associated with vigabatrin: A study of epileptic Argentine patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Moreno MC, Giagante B, Saidon P, Kochen S, Benozzi J, Rosenstein RE. Visual defects associated with vigabatrin: A study of epileptic Argentine patients. Can J Neurol Sci (2005); 32: 459.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>459</start></extent></part><relatedItem type="host"><titleInfo><title>Can J Neurol Sci</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>459</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit140"><titleInfo><title>Reversible anorgasmia with topiramate therapy for migraine (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Newman LC, Broner SW, Lay CL. Reversible anorgasmia with topiramate therapy for migraine (Letter). Neurology (2005); 65: 1333.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>1333</start></extent></part><relatedItem type="host"><titleInfo><title>Neurology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>1333</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit141"><titleInfo><title>Broadening the view of acetaminophen hepatotoxicity (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">O'Grady JG. Broadening the view of acetaminophen hepatotoxicity (Editorial). Hepatology (2005); 42: 1252.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1252</start></extent></part><relatedItem type="host"><titleInfo><title>Hepatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>1252</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit142"><titleInfo><title>Diagnostic clinical features of pentazocine‐induced ulcers</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Prasad HRY, Khaitan BK, Ramam M, Sharma VK, Pandhi RK, Agarwal S, Dhawan A, Jain R, Singh MK. Diagnostic clinical features of pentazocine‐induced ulcers. Int J Dermatol (2005); 44: 910.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>910</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>910</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit143"><titleInfo><title>Updates on acetaminophen toxicity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rowden AK, Norvell J, Eldridge DL, Kirk MA. Updates on acetaminophen toxicity. Med Clin North Am (2005); 89: 1145.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>1145</start></extent></part><relatedItem type="host"><titleInfo><title>Med Clin North Am</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>1145</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit144"><titleInfo><title>Interstitial pneumonitis during lamotrigine therapy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Saravanan N, Otaiku OM, Namushi RN. Interstitial pneumonitis during lamotrigine therapy (Letter). Br J Clin Pharmacol (2005); 60: 666.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>666</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>666</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit145"><titleInfo><title>Effect of valproate on plasma levels of interleukin‐6 in healthy male humans</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shiah IS, Yatham LN, Yeh CB, Ravindran AV. Effect of valproate on plasma levels of interleukin‐6 in healthy male humans. Int Clin Psychopharmacol (2005); 20: 295.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>295</start></extent></part><relatedItem type="host"><titleInfo><title>Int Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>295</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit146"><titleInfo><title>Re: Deterioration of Kearns‐Sayre syndrome following articaine administration for local anesthesia (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stehr SN, Oertel R, Schindler C, Hubler M. Re: Deterioration of Kearns‐Sayre syndrome following articaine administration for local anesthesia (Letter). Clin Neuropharmacol (2005); 28: 253.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>253</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Neuropharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>253</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit147"><titleInfo><title>Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry (2005); 76: 1664.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>1664</start></extent></part><relatedItem type="host"><titleInfo><title>J Neurol Neurosurg Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>1664</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit148"><titleInfo><title>6. Non‐steroidal Anti‐inflammatory Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit149"><titleInfo><title>Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Anandacoomarasamy A, Kannagara S, Barnsley L. Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis (Letter). Intern Med J (2005); 35: 638.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>638</start></extent></part><relatedItem type="host"><titleInfo><title>Intern Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>638</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit150"><titleInfo><title>Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec®, diclofenac, and naproxen in a population based cohort study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ashworth NL, Peloso PM, Muhajarine N, Stang M. Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec®, diclofenac, and naproxen in a population based cohort study. J Rheumatol (2005); 32: 2212.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>2212</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>2212</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit151"><titleInfo><title>Distal lower extremity paresthesia and foot drop developing during adalimumab therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Berthelot CN, George SJ, Hsu S. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol (2005); 53: S260.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>S260</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>S260</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit152"><titleInfo><title>Multifocal motor neuropathy during treatment with infliximab (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cocito D, Bergamasco B, Tavella A, Poglio F, Paolasso I, Costa P, Ciaramitaro P, Isoardo G. Multifocal motor neuropathy during treatment with infliximab (Letter). J Peripher Nerv Syst (2005); 10: 386.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>386</start></extent></part><relatedItem type="host"><titleInfo><title>J Peripher Nerv Syst</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>386</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit153"><titleInfo><title>Favourable issue of a fulminant hepatitis associated with sulfasalazine DRESS syndrome without liver transplantation (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Descloux E, Argaud L, Dumrotier J, Scoazec JY, Boillot O, Robert D. Favourable issue of a fulminant hepatitis associated with sulfasalazine DRESS syndrome without liver transplantation (Letter). Intensive Care Med (2005); 31: 1727.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>1727</start></extent></part><relatedItem type="host"><titleInfo><title>Intensive Care Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>1727</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit154"><titleInfo><title>Risk of adverse gastrointestinal outcomes in patients taking cyclo‐oxygenase‐2 inhibitors or conventional non‐steroidal anti‐inflammatory drugs: Population based nested case‐control analysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hippisley‐Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo‐oxygenase‐2 inhibitors or conventional non‐steroidal anti‐inflammatory drugs: Population based nested case‐control analysis. Br Med J (2005); 331: 1310.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>331</number></detail><extent unit="pages"><start>1310</start></extent></part><relatedItem type="host"><titleInfo><title>Br Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>331</number></detail><extent unit="pages"><start>1310</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit155"><titleInfo><title>Early presentation with angioedema and urticaria in cross‐reactive hypersensitivity to nonsteroidal antiinflammatory drugs among young, Asian, atopic children</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kidon MI, Kang LW, Chin CW, Hoon LS, See Y, Goh A, Lin JTP, Chay OM. Early presentation with angioedema and urticaria in cross‐reactive hypersensitivity to nonsteroidal antiinflammatory drugs among young, Asian, atopic children. Pediatrics (2005); 116: E675.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>E675</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatrics</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>E675</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit156"><titleInfo><title>Comparison of reporting of Stevens‐Johnson syndrome and toxic epidermal necrolysis in association with selective COX‐2 inhibitors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">La Grenade L, Lee L, Weaver J, Bonnel R, Karwoski C, Governale L, Brinker A. Comparison of reporting of Stevens‐Johnson syndrome and toxic epidermal necrolysis in association with selective COX‐2 inhibitors. Drug Saf (2005); 28: 917.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>917</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>917</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit157"><titleInfo><title>Cerebral MRI is necessary in patients with rheumatoid arthritis and uveitis before undergoing therapy with TNF‐α blocking agents</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Limmroth V, Thimm C, Hudde T, Fuchsluger T, Wanke I. Cerebral MRI is necessary in patients with rheumatoid arthritis and uveitis before undergoing therapy with TNF‐α blocking agents. Rheumatology (2005); 44: 1373.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1373</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1373</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit158"><titleInfo><title>Multiple drug intolerance including etoricoxib</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Morais‐Almeida M, Marinho S, Rosa S, Gaspar A, Rosado‐Pinto JE. Multiple drug intolerance including etoricoxib. Allergy (2005); 61: 144.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>144</start></extent></part><relatedItem type="host"><titleInfo><title>Allergy</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>144</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit159"><titleInfo><title>Short‐term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti‐inflammatory drugs</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nettis E, Colanardi MC, Ferrannini A, Vacca A, Tursi A. Short‐term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti‐inflammatory drugs. Ann Allergy Asthma Immunol (2005); 95: 438.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><extent unit="pages"><start>438</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Allergy Asthma Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>95</number></detail><extent unit="pages"><start>438</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit160"><titleInfo><title>Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sperandio M, Beedgen B, Feneberg R, Huppertz C, Brussau J, Poschl J, Linderkamp O. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. Pediatrics (2005); 116: 1361.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>1361</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatrics</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>1361</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit161"><titleInfo><title>Acute bacterial meningitis in a patient receiving ibuprofen</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tamburini J, Grimaldi D, Bricaire F, Bossi P. Acute bacterial meningitis in a patient receiving ibuprofen. J Infect (2005); 51: 336.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>336</start></extent></part><relatedItem type="host"><titleInfo><title>J Infect</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>336</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit162"><titleInfo><title>7. CNS Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit163"><titleInfo><title>Does N‐desmethylolanzapine increase, or reduce, the risk for antipsychotic‐induced metabolic syndrome? (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Albers LJ, Ozdemir V, Marder SR, Raggi MA, Aravagiri M, Endrenyi L, Reist C. Does N‐desmethylolanzapine increase, or reduce, the risk for antipsychotic‐induced metabolic syndrome? (Letter). J Clin Psychopharmacol (2005); 25: 627.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>627</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>627</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit164"><titleInfo><title>Assessing cardiovascular risks of olanzapine treatment: A 6‐month study versus haloperidol in schizophrenia patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Barak Y, Swartz M, Plopsky I. Assessing cardiovascular risks of olanzapine treatment: A 6‐month study versus haloperidol in schizophrenia patients. Int Clin Psychopharmacol (2005); 20: 315.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>315</start></extent></part><relatedItem type="host"><titleInfo><title>Int Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>315</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit165"><titleInfo><title>Trends in the prescribing of antidepressants following acute myocardial infarction, 1993‐2002</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Benazon NR, Mamdani MM, Coyne JC. Trends in the prescribing of antidepressants following acute myocardial infarction, 1993‐2002. Psychosom Med (2005); 67: 916.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>916</start></extent></part><relatedItem type="host"><titleInfo><title>Psychosom Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>67</number></detail><extent unit="pages"><start>916</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit166"><titleInfo><title>Efficacy and safety of modafinil film‐coated tablets in children and adolescents with attention‐deficit/hyperactivity disorder: Results of a randomized, double‐blind, placebo‐controlled, flexible‐dose study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L. Efficacy and safety of modafinil film‐coated tablets in children and adolescents with attention‐deficit/hyperactivity disorder: Results of a randomized, double‐blind, placebo‐controlled, flexible‐dose study. Pediatrics (2005); 116: E777.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>E777</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatrics</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>116</number></detail><extent unit="pages"><start>E777</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit167"><titleInfo><title>Clinicians' recognition of the metabolic adverse effects of antipsychotic medications</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Buckley PF, Miller DD, Singer B, Arena J, Stirewalt EM. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res (2005); 79: 281.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>281</start></extent></part><relatedItem type="host"><titleInfo><title>Schizophr Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>281</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit168"><titleInfo><title>Comments on article by Albers et al ‐ “Low‐dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: A prospective dose‐adjusted drug interaction strategy” (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chiu CC, Lu ML. Comments on article by Albers et al ‐ “Low‐dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: A prospective dose‐adjusted drug interaction strategy” (Letter). J Clin Psychopharmacol (2005); 25: 626.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>626</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>626</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit169"><titleInfo><title>Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">D'Arrigo C, Migliardi G, Santoro V, Morgante L, Muscatello MR, Ancione M, Spina E. Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. Pharmacol Res (2005); 52: 497.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>497</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacol Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><extent unit="pages"><start>497</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit170"><titleInfo><title>Impaired glucose homeostasis after imipramine intake in a diabetic patient (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Derijks HJ, De Koning FHP, Meyboom RH, Heerdink ER, Spooren PFMJ, Egberts ACG. Impaired glucose homeostasis after imipramine intake in a diabetic patient (Letter). J Clin Psychopharmacol (2005); 25: 621.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>621</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>621</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit171"><titleInfo><title>Respiratory dyskinesia as discontinuation effect of risperidone (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ehrt U, Fritze F, Aarsland D. Respiratory dyskinesia as discontinuation effect of risperidone (Letter). J Clin Psychopharmacol (2005); 25: 609.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>609</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>609</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit172"><titleInfo><title>Understanding toxidromes: Serotonin toxicity ‐ A commentary on Montanes‐Rada et al (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gillman PK. Understanding toxidromes: Serotonin toxicity ‐ A commentary on Montanes‐Rada et al (Letter). J Clin Psychopharmacol (2005); 25: 625.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>625</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>625</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit173"><titleInfo><title>Acute dystonia with intramuscular olanzapine in adolescent mania: A report (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goyal N, Thakur A, Sinha VK. Acute dystonia with intramuscular olanzapine in adolescent mania: A report (Letter). Aust N Z J Psychiatry (2005); 39: 1046.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1046</start></extent></part><relatedItem type="host"><titleInfo><title>Aust N Z J Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1046</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit174"><titleInfo><title>Safety and immunogenicity of a nicotine conjugate vaccine in current smokers</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, De Vos A, Horwith G, Pentel PR. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther (2005); 78: 456.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>456</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacol Ther</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>456</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit175"><titleInfo><title>The prevalence of hyperprolactinemia after long‐term haloperidol use in patients with chronic schizophrenia (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jeong CY, Conley RR, Kelly DL, Shim JC. The prevalence of hyperprolactinemia after long‐term haloperidol use in patients with chronic schizophrenia (Letter). J Clin Psychopharmacol (2005); 25: 613.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>613</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>613</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit176"><titleInfo><title>Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9‐hydroxyrisperidone in schizophrenic patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jung SM, Kim KA, Cho HK, Jung IG, Park PW, Byun WT, Park JY. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9‐hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther (2005); 78: 520.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>520</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Pharmacol Ther</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><extent unit="pages"><start>520</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit177"><titleInfo><title>Antidepressant and statin interactions: A review and case report of simvastatin and nefazodone‐induced rhabdomyolysis and transaminitis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Karnik NS, Maldonado JR. Antidepressant and statin interactions: A review and case report of simvastatin and nefazodone‐induced rhabdomyolysis and transaminitis. Psychosomatics (2005); 46: 565.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>565</start></extent></part><relatedItem type="host"><titleInfo><title>Psychosomatics</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>565</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit178"><titleInfo><title>Necrotizing enterocolitis after antipsychotic treatment involving clozapine and review of severe digestive complications ‐ A case report</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Khaldi S, Gourevitch R, Matmar M, Llory A, Olie JP, Chauvelot‐Moachon L. Necrotizing enterocolitis after antipsychotic treatment involving clozapine and review of severe digestive complications ‐ A case report. Pharmacopsychiatry (2005); 38: 220.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>220</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacopsychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>220</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit179"><titleInfo><title>Antidepressants, warfarin, and the risk of hemorrhage</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kurdyak PA, Juurlink DN, Kopp A, Herrmann N, Mamdani MM. Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol (2005); 25: 561.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>561</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>561</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit180"><titleInfo><title>Recurrent heat‐related illnesses during antipsychotic treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kwok JSS, Chan TYK. Recurrent heat‐related illnesses during antipsychotic treatment. Ann Pharmacother (2005); 39: 1940.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1940</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1940</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit181"><titleInfo><title>Ziprasidone and psychosis in Parkinson disease (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Micheli R, Taubenslag N, Gatto E, Scorticati MC. Ziprasidone and psychosis in Parkinson disease (Letter). Clin Neuropharmacol (2005); 28: 254.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>254</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Neuropharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>254</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit182"><titleInfo><title>Diplopia with citalopram ‐ A case report (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mowla A, Ghanizadeh A, Ashkani H. Diplopia with citalopram ‐ A case report (Letter). J Clin Psychopharmacol (2005); 25: 623.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>623</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>623</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit183"><titleInfo><title>Priapism associated with oxcarbazepine, aripiprazole, and lithium (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Negin B, Murphy TK. Priapism associated with oxcarbazepine, aripiprazole, and lithium (Letter). J Am Acad Child Adolesc Psychiatry (2005); 44: 1223.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1223</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Child Adolesc Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1223</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit184"><titleInfo><title>Safety of intravenous methamphetamine administration during treatment with bupropion</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Newton TF, Roache JD, De La Garza R, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R. Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology (Berl) (2005); 182: 426.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>182</number></detail><extent unit="pages"><start>426</start></extent></part><relatedItem type="host"><titleInfo><title>Psychopharmacology (Berl)</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>182</number></detail><extent unit="pages"><start>426</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit185"><titleInfo><title>Clomipramine‐induced hypersensitivity syndrome with unusual clinical features</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nishimura Y, Kitoh A, Yoshida Y, Tanaka T. Clomipramine‐induced hypersensitivity syndrome with unusual clinical features. J Am Acad Dermatol (2005); 53: S231.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>S231</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>S231</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit186"><titleInfo><title>Paroxetine‐associated spontaneous sexual stimulation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pae CU, Kim TS, Lee KU, Kim JJ, Lee CU, Lee SJ, Lee C, Paik IH. Paroxetine‐associated spontaneous sexual stimulation. Int Clin Psychopharmacol (2005); 20: 339.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>339</start></extent></part><relatedItem type="host"><titleInfo><title>Int Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>339</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit187"><titleInfo><title>Tardive dystonia associated with ziprasidone (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Papapetropoulos S, Wheeler S, Singer C. Tardive dystonia associated with ziprasidone (Letter). Am J Psychiatry (2005); 162: 2191.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>162</number></detail><extent unit="pages"><start>2191</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>162</number></detail><extent unit="pages"><start>2191</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit188"><titleInfo><title>Periodic restless legs syndrome associated with quetiapine use ‐ A case report (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pinninti NR, Mago R, Townsend J, Doghramji K. Periodic restless legs syndrome associated with quetiapine use ‐ A case report (Letter). J Clin Psychopharmacol (2005); 25: 617.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>617</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>617</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit189"><titleInfo><title>Venlafaxine‐induced urinary incontinence resolved after switching to sertraline</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Polimeni G, Salvo F, Cutroneo P, Nati G, Russo A, Giustini ES, Spina E. Venlafaxine‐induced urinary incontinence resolved after switching to sertraline. Clin Neuropharmacol (2005); 28: 247.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>247</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Neuropharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>247</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit190"><titleInfo><title>Modafinil‐induced irritability and aggression? A report of 2 bipolar patients (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ranjan S, Chandra PS. Modafinil‐induced irritability and aggression? A report of 2 bipolar patients (Letter). J Clin Psychopharmacol (2005); 25: 628.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>628</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>628</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit191"><titleInfo><title>How safe is long‐term benzodiazepine pharmacotherapy? (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schwartz RA. How safe is long‐term benzodiazepine pharmacotherapy? (Letter). J Clin Psychopharmacol (2005); 25: 624.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>624</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>624</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit192"><titleInfo><title>Adverse effects associated with extra doses of bupropion</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shepherd G. Adverse effects associated with extra doses of bupropion. Pharmacotherapy (2005); 25: 1378.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1378</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1378</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit193"><titleInfo><title>Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stebbing J, Waters L, Davies L, Mandalia S, Nelson M, Gazzard B, Bower M. Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study (Letter). J Clin Oncol (2005); 23: 8134.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>8134</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>8134</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit194"><titleInfo><title>Quetiapine use in a patient with chronic schizophrenia and severe parkinsonism</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stoner SC, Lea JW, Wolf AL, Berges AA. Quetiapine use in a patient with chronic schizophrenia and severe parkinsonism. Pharmacotherapy (2005); 25: 1651.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1651</start></extent></part><relatedItem type="host"><titleInfo><title>Pharmacotherapy</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1651</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit195"><titleInfo><title>Acute effects of clozapine‐fluvoxamine combination (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vaios P, Sofia T, Dimitrios P, Venetsanos M. Acute effects of clozapine‐fluvoxamine combination (Letter). Schizophr Res (2005); 79: 345.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>345</start></extent></part><relatedItem type="host"><titleInfo><title>Schizophr Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>345</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit196"><titleInfo><title>Risk of death in elderly users of conventional vs. atypical antipsychotic medications</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, Brookhart MA. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med (2005); 353: 2335.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2335</start></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2335</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit197"><titleInfo><title>Suicidal ideation among children taking atomoxetine (Strattera)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wooltorton E. Suicidal ideation among children taking atomoxetine (Strattera). Can Med Assoc J (2005); 173: 1447.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>173</number></detail><extent unit="pages"><start>1447</start></extent></part><relatedItem type="host"><titleInfo><title>Can Med Assoc J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>173</number></detail><extent unit="pages"><start>1447</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit198"><titleInfo><title>The efficacy and safety of quetiapine for treatment of geriatric psychosis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yang CH, Tsai SJ, Hwang JP. The efficacy and safety of quetiapine for treatment of geriatric psychosis. J Psychopharmacol (2005); 19: 661.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>661</start></extent></part><relatedItem type="host"><titleInfo><title>J Psychopharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>661</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit199"><titleInfo><title>8. Anti‐neoplastic Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit200"><titleInfo><title>Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Abali H, Eren OO, Dizdar O, Karadag O, Erman M, Yilmaz A, Uluc K, Erdem I, Turker A. Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma. Leuk Lymphoma (2005); 46: 1825.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1825</start></extent></part><relatedItem type="host"><titleInfo><title>Leuk Lymphoma</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1825</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit201"><titleInfo><title>Nimotuzumab: Evidence of clinical benefit without rash (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Allan DGP. Nimotuzumab: Evidence of clinical benefit without rash (Letter). Oncologist (2005); 10: 760.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>760</start></extent></part><relatedItem type="host"><titleInfo><title>Oncologist</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>760</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit202"><titleInfo><title>Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5‐fluorouracil therapy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Altundag O, Altundag K, Silay K, Turen S. Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5‐fluorouracil therapy (Letter). Med Hypotheses (2005); 65: 1196.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>1196</start></extent></part><relatedItem type="host"><titleInfo><title>Med Hypotheses</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>65</number></detail><extent unit="pages"><start>1196</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit203"><titleInfo><title>Intravesical bacillus Calmette‐Guerin therapy: Experience with a reduced dwell‐time in patients with pronounced side‐effects</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Andius P, Fehrling M, Holmang S. Intravesical bacillus Calmette‐Guerin therapy: Experience with a reduced dwell‐time in patients with pronounced side‐effects. BJU Int (2005); 96: 1290.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>1290</start></extent></part><relatedItem type="host"><titleInfo><title>BJU Int</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>1290</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit204"><titleInfo><title>Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2‐positive recurrent breast cancer: Findings from a case series (German, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ardavanis A, Tryfonopoulos D, Orfanos G, Karamouzis M, Scorilas A, Alexopoulos A, Rigatos G. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2‐positive recurrent breast cancer: Findings from a case series (German, English Abstract). Onkologie (2005); 28: 558.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>558</start></extent></part><relatedItem type="host"><titleInfo><title>Onkologie</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>558</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit205"><titleInfo><title>Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: An integrated analysis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Armstrong DK, Spriggs D, Levin J, Poulin R, Lane S. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: An integrated analysis. Oncologist (2005); 10: 686.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>686</start></extent></part><relatedItem type="host"><titleInfo><title>Oncologist</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>686</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit206"><titleInfo><title>Side effects related to cancer treatment ‐ Case 2. Splenic rupture following pegfilgrastim</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Arshad M, Seiter K, Bilaniuk J, Qureshi A, Patil A, Ramaswamy G, Liu DL. Side effects related to cancer treatment ‐ Case 2. Splenic rupture following pegfilgrastim. J Clin Oncol (2005); 23: 8533.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>8533</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>8533</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit207"><titleInfo><title>Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baize N, Abu Shalaa A, Berthier F, Demarquay JFO, Bernard JL, Rahiu A, Piche T, Huet PM, Ran A, Caroli‐Bosc FX. Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma. Gastroenterol Clin Biol (2005); 29: 1006.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>1006</start></extent></part><relatedItem type="host"><titleInfo><title>Gastroenterol Clin Biol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>1006</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit208"><titleInfo><title>Hypercalcemia due to all trans retinoic acid in the treatment of acute promyelocytic leukemia potentiated by voriconazole</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bennett MT, Sirrs S, Yeung JK, Smith CA. Hypercalcemia due to all trans retinoic acid in the treatment of acute promyelocytic leukemia potentiated by voriconazole. Leuk Lymphoma (2005); 46: 1829.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1829</start></extent></part><relatedItem type="host"><titleInfo><title>Leuk Lymphoma</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1829</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit209"><titleInfo><title>Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer (2005); 104: 2141.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><extent unit="pages"><start>2141</start></extent></part><relatedItem type="host"><titleInfo><title>Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><extent unit="pages"><start>2141</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit210"><titleInfo><title>Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bloch J, Rixe O, Meric JB, Delgado A, Khayat D. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. Curr Med Res Opin (2005); 21: 1763.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1763</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Med Res Opin</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>1763</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit211"><titleInfo><title>Life‐threatening complications from doxorubicin‐docetaxel chemotherapy for breast cancer (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brain EGC, Bachelot T, Serin D. Life‐threatening complications from doxorubicin‐docetaxel chemotherapy for breast cancer (Reply). JAMA (2005); 294: 2166.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2166</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2166</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit212"><titleInfo><title>Pityriasis rosea‐like eruption during treatment with imatinib mesylate: Description of 3 cases</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Brazzelli V, Prestinari F, Roveda E, Barbagallo T, Bellani E, Vassallo C, Orlandi E, Passamonti F, Borroni G. Pityriasis rosea‐like eruption during treatment with imatinib mesylate: Description of 3 cases. J Am Acad Dermatol (2005); 53: S240.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>S240</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>S240</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit213"><titleInfo><title>A case of all‐trans retinoic acid‐induced myositis in the treatment of acute promyelocytic leukaemia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chan KH, Yuen SLS, Joshua D. A case of all‐trans retinoic acid‐induced myositis in the treatment of acute promyelocytic leukaemia. Clin Lab Haematol (2005); 27: 399.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>399</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Lab Haematol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>399</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit214"><titleInfo><title>Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Corso A, Mangiacavalli S, Nosari A, Castagnola C, Zappasodi P, Cafro AM, Astori C, Bonfichi M, Varettoni M, Rusconi C, Troletti D, Pascutto C, Morra E, Lazzarino M. Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. Bone Marrow Transplant (2005); 36: 951.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>951</start></extent></part><relatedItem type="host"><titleInfo><title>Bone Marrow Transplant</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>951</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit215"><titleInfo><title>Phase I and pharmacokinetic study of the dolastatin‐15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cunningham C, Appleman LJ, Kirvan‐Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP. Phase I and pharmacokinetic study of the dolastatin‐15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2005); 11: 7825.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>7825</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Cancer Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>7825</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit216"><titleInfo><title>Thalidomide‐associated thrombocytopenia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Duyvendak M, Naunton M, Kingma BJ, Brouwers JRBJ. Thalidomide‐associated thrombocytopenia. Ann Pharmacother (2005); 39: 1936.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1936</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1936</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit217"><titleInfo><title>Reversibility of trastuzumab‐related cardiotoxicity: New insights based on clinical course and response to medical treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab‐related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol (2005); 23: 7820.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>7820</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>7820</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit218"><titleInfo><title>Medication safety in the ambulatory chemotherapy setting</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gandhi TK, Bartel SB, Shulman LN, Verrier D, Burdick E, Cleary A, Rothschild JM, Leape LL, Bates DW. Medication safety in the ambulatory chemotherapy setting. Cancer (2005); 104: 2477.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><extent unit="pages"><start>2477</start></extent></part><relatedItem type="host"><titleInfo><title>Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><extent unit="pages"><start>2477</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit219"><titleInfo><title>Combined therapy with weekly irinotecan, infusional 5‐fluorouracil and the selective COX‐2 inhibitor rofecoxib is a safe and effective second‐line treatment in metastatic colorectal cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gasparini G, Gattuso D, Morabito A, Longo R, Torino F, Sarmiento R, Vitale S, Gamucci T, Mariani L. Combined therapy with weekly irinotecan, infusional 5‐fluorouracil and the selective COX‐2 inhibitor rofecoxib is a safe and effective second‐line treatment in metastatic colorectal cancer. Oncologist (2005); 10: 710.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>710</start></extent></part><relatedItem type="host"><titleInfo><title>Oncologist</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>710</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit220"><titleInfo><title>Side effects related to cancer treatment ‐ Case 1. Hepatitis following treatment with gefitinib</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ho C, Davis J, Anderson F, Bebb G, Murray N. Side effects related to cancer treatment ‐ Case 1. Hepatitis following treatment with gefitinib. J Clin Oncol (2005); 23: 8531.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>8531</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>8531</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit221"><titleInfo><title>Helping melanoma patients decide whether to choose adjuvant high‐dose interferon‐α2b</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hurley KE, Chapman PB. Helping melanoma patients decide whether to choose adjuvant high‐dose interferon‐α2b. Oncologist (2005); 10: 739.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>739</start></extent></part><relatedItem type="host"><titleInfo><title>Oncologist</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>739</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit222"><titleInfo><title>High‐dose cyclophosphamide and MESNA infusion can cause acute atrial fibrillation (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ifran A, Kaptan K, Beyan C. High‐dose cyclophosphamide and MESNA infusion can cause acute atrial fibrillation (Letter). Am J Hematol (2005); 80: 247.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>247</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Hematol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>247</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit223"><titleInfo><title>A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer (2005); 104: 2222.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><extent unit="pages"><start>2222</start></extent></part><relatedItem type="host"><titleInfo><title>Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><extent unit="pages"><start>2222</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit224"><titleInfo><title>Very acute cardiac toxicity during BEAC chemotherapy in non‐Hodgkin's lymphoma patients undergoing autologous stem cell transplantation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kuittinen T, Husso‐Saastamoinen M, Sipola P, Vuolteenaho O, Ala‐Kopsala M, Nousiainen T, Jantunen E, Hartikainen J. Very acute cardiac toxicity during BEAC chemotherapy in non‐Hodgkin's lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant (2005); 36: 1077.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>1077</start></extent></part><relatedItem type="host"><titleInfo><title>Bone Marrow Transplant</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>1077</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit225"><titleInfo><title>Kinase inhibitor‐induced pustules (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Laffitte E, Saurat JH. Kinase inhibitor‐induced pustules (Editorial). Dermatology (2005); 211: 305.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>211</number></detail><extent unit="pages"><start>305</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>211</number></detail><extent unit="pages"><start>305</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit226"><titleInfo><title>Survey of oxaliplatin‐associated neurotoxicity using an interview‐based questionnaire in patients with metastatic colorectal cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, Thomas RR, Grem JL. Survey of oxaliplatin‐associated neurotoxicity using an interview‐based questionnaire in patients with metastatic colorectal cancer. BMC Cancer (2005); 5: 116.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>116</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>116</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit227"><titleInfo><title>Trastuzumab cardiac side effects: Only time will tell</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Levine MN. Trastuzumab cardiac side effects: Only time will tell. J Clin Oncol (2005); 23: 7775.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>7775</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>7775</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit228"><titleInfo><title>Cost effectiveness of cardioprotective strategies in patients with aggressive non‐Hodgkin's lymphoma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Limat S, Demesmay K, Fagnoni P, Voillat L, Bernard Y, Deconinck E, Brion A, Arveux P, Cahn JY, Woronoff‐Lemsi MC. Cost effectiveness of cardioprotective strategies in patients with aggressive non‐Hodgkin's lymphoma. Clin Drug Invest (2005); 25: 719.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>719</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Drug Invest</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>719</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit229"><titleInfo><title>Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood (2005); 106: 3777.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>3777</start></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>3777</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit230"><titleInfo><title>Allergic‐type reactions to oxaliplatin: Retrospective analysis of 42 patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Maindrault‐Goebel F, Andre T, Tournigand C, Louvet C, Perez‐Staub N, Zeghib N, De Gramont A. Allergic‐type reactions to oxaliplatin: Retrospective analysis of 42 patients. Eur J Cancer (2005); 41: 2262.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>2262</start></extent></part><relatedItem type="host"><titleInfo><title>Eur J Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>2262</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit231"><titleInfo><title>Topotecan as second‐line therapy for ovarian cancer: Dosage versus toxicity</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Markman M. Topotecan as second‐line therapy for ovarian cancer: Dosage versus toxicity. Oncologist (2005); 10: 695.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>695</start></extent></part><relatedItem type="host"><titleInfo><title>Oncologist</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>695</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit232"><titleInfo><title>Life‐threatening complications from doxorubicin‐docetaxel chemotherapy for breast cancer (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Martin M, Vogel C, Crown J, Mackey J. Life‐threatening complications from doxorubicin‐docetaxel chemotherapy for breast cancer (Letter). JAMA (2005); 294: 2166.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2166</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2166</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit233"><titleInfo><title>Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol (2005); 23: 7614.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>7614</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>7614</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit234"><titleInfo><title>Low‐dose thalidomide‐induced agranulocytosis in a multiple myeloma patient treated at diagnosis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mazzotta S, Gozzetti A, Pirrotta MT, Bocchia M, Sammassimo S, Bucalossi A, Lauria F. Low‐dose thalidomide‐induced agranulocytosis in a multiple myeloma patient treated at diagnosis. Leuk Lymphoma (2005); 46: 1837.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1837</start></extent></part><relatedItem type="host"><titleInfo><title>Leuk Lymphoma</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1837</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit235"><titleInfo><title>Ovarian cyst formation in patients using tamoxifen for breast cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Metindir J, Aslan S, Bilir G. Ovarian cyst formation in patients using tamoxifen for breast cancer. Jpn J Clin Oncol (2005); 35: 607.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>607</start></extent></part><relatedItem type="host"><titleInfo><title>Jpn J Clin Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>607</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit236"><titleInfo><title>Cetuximab‐induced acne</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Molinari E, De Quatrebarbes J, Andre T, Aractingi S. Cetuximab‐induced acne. Dermatology (2005); 211: 330.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>211</number></detail><extent unit="pages"><start>330</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>211</number></detail><extent unit="pages"><start>330</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit237"><titleInfo><title>Cetuximab‐associated acneiform eruption</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Moss JE, Burtness B. Cetuximab‐associated acneiform eruption. N Engl J Med (2005); 353: e17.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>e17</start></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>e17</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit238"><titleInfo><title>Reducing‐adverse drug events in the outpatient chemotherapy setting ‐ Attention must be paid (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nebeker JR, Bennett CL. Reducing‐adverse drug events in the outpatient chemotherapy setting ‐ Attention must be paid (Editorial). Cancer (2005); 104: 2289.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><extent unit="pages"><start>2289</start></extent></part><relatedItem type="host"><titleInfo><title>Cancer</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>104</number></detail><extent unit="pages"><start>2289</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit239"><titleInfo><title>Insulin resistance as an adverse effect of leuprolide and bicalutamide treatment (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Paniagua MA, Hirsch IB. Insulin resistance as an adverse effect of leuprolide and bicalutamide treatment (Letter). J Gerontol A Biol Sci Med Sci (2005); 60: 1283.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1283</start></extent></part><relatedItem type="host"><titleInfo><title>J Gerontol A Biol Sci Med Sci</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1283</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit240"><titleInfo><title>Severe cutaneous toxicity following treatment with gefitinib (ZD1839) (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pascual JC, Belinchon I, Sivera F, Yuste A. Severe cutaneous toxicity following treatment with gefitinib (ZD1839) (Letter). Br J Dermatol (2005); 153: 1222.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>153</number></detail><extent unit="pages"><start>1222</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>153</number></detail><extent unit="pages"><start>1222</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit241"><titleInfo><title>Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL‐2) administration in a patient with follicular large cell lymphoma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Polder K, Wang CY, Duvic M, Diwan AH, Parks D, Jankov A, Walker PL, Tong AT, Bull J, Dang NH. Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL‐2) administration in a patient with follicular large cell lymphoma. Leuk Lymphoma (2005); 46: 1807.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1807</start></extent></part><relatedItem type="host"><titleInfo><title>Leuk Lymphoma</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1807</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit242"><titleInfo><title>Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pui CH, Pei DQ, Sandlund JT, Campana D, Ribeiro RC, Razzouk BI, Rubnitz JE, Howard SC, Hijiya N, Jeha S, Cheng C, Downing JR, Evans WE, Relling MV, Hudson M. Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol (2005); 23: 7936.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>7936</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>7936</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit243"><titleInfo><title>Therapy‐related leukemia: Clinical characteristics and analysis of new molecular risk factors in 96 adult patients</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rund D, Krichevsky S, Bar‐Cohen S, Goldschmidt N, Kedmi M, Malik E, Gural A, Shafran‐Tikva S, Ben‐Neriah S, Ben‐Yehuda D. Therapy‐related leukemia: Clinical characteristics and analysis of new molecular risk factors in 96 adult patients. Leukemia (2005); 19: 1919.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>1919</start></extent></part><relatedItem type="host"><titleInfo><title>Leukemia</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>1919</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit244"><titleInfo><title>Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenstrom's macroglobulinemia after sequential treatment with chlorambucil and fludarabine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shin SJ, Chun SH, Kim KO, Kim MK, Lee KH, Hyun MS, Cho HS. Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenstrom's macroglobulinemia after sequential treatment with chlorambucil and fludarabine. Jpn J Clin Oncol (2005); 35: 622.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>622</start></extent></part><relatedItem type="host"><titleInfo><title>Jpn J Clin Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>622</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit245"><titleInfo><title>Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stefoni V, Alinari L, Musuraca G, Tani M, Marchi E, Gabriele A, Fina M, Pileri S, Baccarani M, Zinzani PL. Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas (Letter). Leuk Lymphoma (2005); 46: 1839.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1839</start></extent></part><relatedItem type="host"><titleInfo><title>Leuk Lymphoma</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1839</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit246"><titleInfo><title>Central hypothyroidism related with bexarotene treatment (Letter) (Spanish)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sucunza N, Garcia‐Muret MP, Rodriguez J, Corcoy R. Central hypothyroidism related with bexarotene treatment (Letter) (Spanish). Med Clin (Barc) (2005); 125: 559.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>559</start></extent></part><relatedItem type="host"><titleInfo><title>Med Clin (Barc)</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>125</number></detail><extent unit="pages"><start>559</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit247"><titleInfo><title>Prevention of chemotherapy‐induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony‐stimulating factor in small‐cell lung cancer: A Dutch randomized phase III study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Timmer‐Bonte JN, De Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan‐Heijnen VC. Prevention of chemotherapy‐induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony‐stimulating factor in small‐cell lung cancer: A Dutch randomized phase III study. J Clin Oncol (2005); 23: 7974.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>7974</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>7974</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit248"><titleInfo><title>Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Travis LB, Hill D, Dores GM, Gospodarowicz M, Van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, Van't Veer MB, Joensuu T, Storm H, Stovall M, Boice JD, Gilbert E, Gail MH. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Nat Cancer Inst (2005); 97: 1428.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><extent unit="pages"><start>1428</start></extent></part><relatedItem type="host"><titleInfo><title>J Nat Cancer Inst</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><extent unit="pages"><start>1428</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit249"><titleInfo><title>Gefitinib in the adjuvant setting: Safety results from a phase III study in patients with completely resected non‐small cell lung cancer</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsuboi M, Kato H, Nagai K, Tsuchiya R, Wada H, Tada H, Ichinose Y, Fukuoka M, Jiang HY. Gefitinib in the adjuvant setting: Safety results from a phase III study in patients with completely resected non‐small cell lung cancer. Anticancer Drugs (2005); 16: 1123.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1123</start></extent></part><relatedItem type="host"><titleInfo><title>Anticancer Drugs</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>1123</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit250"><titleInfo><title>9. Haematological Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit251"><titleInfo><title>Heparin‐induced thrombocytopenia from venous thromboembolism treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Begelman SM, Hursting MJ, Aghababian RV, McCollum D. Heparin‐induced thrombocytopenia from venous thromboembolism treatment. J Intern Med (2005); 258: 563.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>258</number></detail><extent unit="pages"><start>563</start></extent></part><relatedItem type="host"><titleInfo><title>J Intern Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>258</number></detail><extent unit="pages"><start>563</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit252"><titleInfo><title>Long‐term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: A follow‐up report from the Research on Adverse Drug Events and Reports (RADAR) Project</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B, Sharma R, Costello S, Toffelmire EB, Wells GA, Messner HA, Yarnold PR, Trifilio SM, Raisch DW, Kuzel TM, Nissenson A, Lim LC, Tallman MS, Casadevall N. Long‐term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: A follow‐up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood (2005); 106: 3343.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>3343</start></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>3343</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit253"><titleInfo><title>Comments on the important drug interaction of warfarin and sulfamethoxazole (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Campbell JE, Carter WH. Comments on the important drug interaction of warfarin and sulfamethoxazole (Letter). Arch Intern Med (2005); 165: 2540.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>2540</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Intern Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>2540</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit254"><titleInfo><title>Warfarin induction at 5 mg daily is safe with a low risk of anticoagulant overdose: Results of an audit of patients with deep vein thrombosis commencing warfarin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Harper P, Monahan K, Baker B. Warfarin induction at 5 mg daily is safe with a low risk of anticoagulant overdose: Results of an audit of patients with deep vein thrombosis commencing warfarin. Intern Med J (2005); 35: 717.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>717</start></extent></part><relatedItem type="host"><titleInfo><title>Intern Med J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>35</number></detail><extent unit="pages"><start>717</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit255"><titleInfo><title>Safety of heparinization for cerebral aneurysm coiling soon after external ventriculostomy drain placement</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hoh BL, Nogueira RG, Ledezma CJ, Pryor JC, Ogilvy CS. Safety of heparinization for cerebral aneurysm coiling soon after external ventriculostomy drain placement. Neurosurgery (2005); 57: 845.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>845</start></extent></part><relatedItem type="host"><titleInfo><title>Neurosurgery</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>845</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit256"><titleInfo><title>Comments on the important drug interaction of warfarin and sulfamethoxazole (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Holbrook A, Pereira J. Comments on the important drug interaction of warfarin and sulfamethoxazole (Reply). Arch Intern Med (2005); 165: 2540.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>2540</start></extent></part><relatedItem type="host"><titleInfo><title>Arch Intern Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>165</number></detail><extent unit="pages"><start>2540</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit257"><titleInfo><title>Safety and efficacy of ximelagatran: Meta‐analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Iorio A, Guercini F, Ferrante F, Nenci GG. Safety and efficacy of ximelagatran: Meta‐analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. Curr Pharm Des (2005); 11: 3893.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>3893</start></extent></part><relatedItem type="host"><titleInfo><title>Curr Pharm Des</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>3893</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit258"><titleInfo><title>What is the appropriate anticoagulation therapy in patients with a history of heparin‐induced thrombocytopenia? (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kopterides P. What is the appropriate anticoagulation therapy in patients with a history of heparin‐induced thrombocytopenia? (Letter). Anesth Analg (2005); 101: 1885.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>101</number></detail><extent unit="pages"><start>1885</start></extent></part><relatedItem type="host"><titleInfo><title>Anesth Analg</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>101</number></detail><extent unit="pages"><start>1885</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit259"><titleInfo><title>Safety of heparinization for cerebral aneurysm coiling soon after external ventriculostomy drain placement ‐ Discussion</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Macdonald RL, Lawton MT, Awad IA, Amar AP. Safety of heparinization for cerebral aneurysm coiling soon after external ventriculostomy drain placement ‐ Discussion. Neurosurgery (2005); 57: 848.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>848</start></extent></part><relatedItem type="host"><titleInfo><title>Neurosurgery</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>848</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit260"><titleInfo><title>The incidence of heparin‐induced thrombocytopenia in medical patients treated with low‐molecular‐weight heparin: A prospective cohort study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Prandoni P, Siragusa S, Girolami B, Fabris F. The incidence of heparin‐induced thrombocytopenia in medical patients treated with low‐molecular‐weight heparin: A prospective cohort study. Blood (2005); 106: 3049.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>3049</start></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>3049</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit261"><titleInfo><title>A spontaneous intramural hematoma of the bowel presenting as obstruction in a child receiving low‐molecular‐weight heparin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shaw PH, Ranganathan S, Gaines B. A spontaneous intramural hematoma of the bowel presenting as obstruction in a child receiving low‐molecular‐weight heparin. J Pediatr Hematol Oncol (2005); 27: 558.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>558</start></extent></part><relatedItem type="host"><titleInfo><title>J Pediatr Hematol Oncol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>558</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit262"><titleInfo><title>Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed‐type heparin allergy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Utikal J, Peitsch WK, Booken D, Velten F, Dempfle CE, Goerdt S, Bayerl C. Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed‐type heparin allergy (Letter). Thromb Haemost (2005); 94: 895.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>895</start></extent></part><relatedItem type="host"><titleInfo><title>Thromb Haemost</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>895</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit263"><titleInfo><title>Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers ‐ A randomized, placebo‐controlled, double‐blind, multi‐dose study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Visich JE, Zuckerman LA, Butine MD, Gunewardena KA, Wild R, Morton KM, Reynolds TC. Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers ‐ A randomized, placebo‐controlled, double‐blind, multi‐dose study. Thromb Haemost (2005); 94: 802.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>802</start></extent></part><relatedItem type="host"><titleInfo><title>Thromb Haemost</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>802</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit264"><titleInfo><title>Anti‐platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Warkentin TE, Cook RJ, Marder VJ, Sheppard JAI, Moore JC, Eriksson BI, Greinacher A, Kelton JG. Anti‐platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood (2005); 106: 3791.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>3791</start></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>3791</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit265"><titleInfo><title>Safety and efficacy of subcutaneous‐only granulocyte‐macrophage colony‐stimulating factor for collateral growth promotion in patients with coronary artery disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zbinden S, Zbinden R, Meier P, Windecker S, Seiler C. Safety and efficacy of subcutaneous‐only granulocyte‐macrophage colony‐stimulating factor for collateral growth promotion in patients with coronary artery disease. J Am Coll Cardiol (2005); 46: 1636.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1636</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Coll Cardiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>46</number></detail><extent unit="pages"><start>1636</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit266"><titleInfo><title>11. Dermatological Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit267"><titleInfo><title>Rectal bleeding following acitretin therapy for discoid lupus erythematosus (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fairhurst DA, Clark SM. Rectal bleeding following acitretin therapy for discoid lupus erythematosus (Letter). Dermatology (2005); 211: 385.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>211</number></detail><extent unit="pages"><start>385</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>211</number></detail><extent unit="pages"><start>385</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit268"><titleInfo><title>Gynaecomastia with oligospermia: An unusual complication of low‐dose methotrexate for pustular psoriasis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pandhi D, Gupta R, Singal A. Gynaecomastia with oligospermia: An unusual complication of low‐dose methotrexate for pustular psoriasis (Letter). Clin Exp Dermatol (2006); 31: 138.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>138</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Dermatol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>138</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit269"><titleInfo><title>Immune thrombocytopenia associated with efalizumab therapy for psoriasis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Warkentin TE, Kwon P. Immune thrombocytopenia associated with efalizumab therapy for psoriasis (Letter). Ann Intern Med (2005); 143: 761.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>143</number></detail><extent unit="pages"><start>761</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Intern Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>143</number></detail><extent unit="pages"><start>761</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit270"><titleInfo><title>12. Immunosuppressive Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit271"><titleInfo><title>Inflammatory reaction after sirolimus‐eluting stent implant</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gomes WJ, Giannotti O, Houssne NA, Catani R, Buffolo E. Inflammatory reaction after sirolimus‐eluting stent implant. Ann Thorac Surg (2005); 80: 1903.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>1903</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Thorac Surg</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>1903</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit272"><titleInfo><title>Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti‐tumor necrosis factor‐α treatment</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti‐tumor necrosis factor‐α treatment. J Rheumatol (2005); 32: 2109.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>2109</start></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>32</number></detail><extent unit="pages"><start>2109</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit273"><titleInfo><title>Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ibanez TC, Tayel MY, Criado AB, Sanz AH, Mola E. Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis (Letter). Rheumatology (2005); 44: 1467.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1467</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1467</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit274"><titleInfo><title>Post‐transplantation proteinuria and sirolimus (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Izzedine H, Brocheriou I, Frances C. Post‐transplantation proteinuria and sirolimus (Letter). N Engl J Med (2005); 353: 2088.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2088</start></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>353</number></detail><extent unit="pages"><start>2088</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit275"><titleInfo><title>Sirolimus‐induced acneiform eruption</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kunzle N, Venetz JP, Pascual M, Panizzon RG, Laffitte E. Sirolimus‐induced acneiform eruption. Dermatology (2005); 211: 366.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>211</number></detail><extent unit="pages"><start>366</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>211</number></detail><extent unit="pages"><start>366</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit276"><titleInfo><title>Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Metzler C, Arlt AC, Gross WL, Brandt J. Peripheral neuropathy in patients with systemic rheumatic diseases treated with leflunomide (Letter). Ann Rheum Dis (2005); 64: 1798.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>1798</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>1798</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit277"><titleInfo><title>Alopecia areata presenting in 2 kidney‐pancreas transplant recipients taking cyclosporine</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Phillips MA, Graves JE, Nunley JR. Alopecia areata presenting in 2 kidney‐pancreas transplant recipients taking cyclosporine. J Am Acad Dermatol (2005); 53: S252.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>S252</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>S252</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit278"><titleInfo><title>Extremely high titer of anti‐human chimeric antibody following re‐treatment with rituximab in a patient with active systemic lupus erythematosus (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Saito K, Nawata M, Iwata S, Tokunaga M, Tanaka Y. Extremely high titer of anti‐human chimeric antibody following re‐treatment with rituximab in a patient with active systemic lupus erythematosus (Letter). Rheumatology (2005); 44: 1462.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1462</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1462</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit279"><titleInfo><title>A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney‐pancreas transplantation: Results at 3 years</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stratta RJ, Alloway RR, Lo A, Hodge EE. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney‐pancreas transplantation: Results at 3 years. Transplant Proc (2005); 37: 3531.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>3531</start></extent></part><relatedItem type="host"><titleInfo><title>Transplant Proc</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>3531</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit280"><titleInfo><title>Myotoxicity occurring with ciclosporin in a patient with atopic dermatitis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wahie S, Meggitt SJ. Myotoxicity occurring with ciclosporin in a patient with atopic dermatitis (Letter). Br J Dermatol (2005); 153: 1238.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>153</number></detail><extent unit="pages"><start>1238</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>153</number></detail><extent unit="pages"><start>1238</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit281"><titleInfo><title>Have methotrexate‐induced liver fibrosis and cirrhosis become rare? A matter for reappraisal of routine liver biopsies (Editorial)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zachariae H. Have methotrexate‐induced liver fibrosis and cirrhosis become rare? A matter for reappraisal of routine liver biopsies (Editorial). Dermatology (2005); 211: 307.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>211</number></detail><extent unit="pages"><start>307</start></extent></part><relatedItem type="host"><titleInfo><title>Dermatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>211</number></detail><extent unit="pages"><start>307</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit282"><titleInfo><title>13. Autonomic Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit283"><titleInfo><title>Myalgia and cramps associated with zolmitriptan</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Alonso‐Navarro H, Jimenez‐Jimenez FJ. Myalgia and cramps associated with zolmitriptan. Clin Neuropharmacol (2005); 28: 241.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>241</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Neuropharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>241</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit284"><titleInfo><title>Ocular side‐effects of tolterodine and oxybutynin, a single‐blind prospective randomized trial (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Altan‐Yaycioglu R, Yaycioglu O, Akova YA. Ocular side‐effects of tolterodine and oxybutynin, a single‐blind prospective randomized trial (Letter). Br J Clin Pharmacol (2005); 60: 669.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>669</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>669</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit285"><titleInfo><title>Refractory generalized edema ‐ An infrequent complication of long‐term pergolide treatment for Parkinson disease</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bianchi M, Castiglioni MG. Refractory generalized edema ‐ An infrequent complication of long‐term pergolide treatment for Parkinson disease. Clin Neuropharmacol (2005); 28: 245.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>245</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Neuropharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>245</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit286"><titleInfo><title>Reversible pisa syndrome in Parkinson's disease during treatment with pergolide ‐ A case report (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cannas A, Solla P, Floris G, Borghero G, Tacconi P, Spissu A. Reversible pisa syndrome in Parkinson's disease during treatment with pergolide ‐ A case report (Letter). Clin Neuropharmacol (2005); 28: 252.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>252</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Neuropharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>252</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit287"><titleInfo><title>Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cheng CR, Sessler DI, Apfel CC. Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting?. Anesth Analg (2005); 101: 1349.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>101</number></detail><extent unit="pages"><start>1349</start></extent></part><relatedItem type="host"><titleInfo><title>Anesth Analg</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>101</number></detail><extent unit="pages"><start>1349</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit288"><titleInfo><title>Sibutramine use associated with reversible hepatotoxicity (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chounta A, Tsiodras S, Zouridakis S, Doumas M, Giamarellou H. Sibutramine use associated with reversible hepatotoxicity (Letter). Ann Intern Med (2005); 143: 763.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>143</number></detail><extent unit="pages"><start>763</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Intern Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>143</number></detail><extent unit="pages"><start>763</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit289"><titleInfo><title>Toxic epidermal necrolysis secondary to timolol, dorzolamide, and latanoprost eyedrops (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Florez A, Roson E, Conde A, Gonzalez B, Garcia‐Doval I, De la Torre C, Cruces M. Toxic epidermal necrolysis secondary to timolol, dorzolamide, and latanoprost eyedrops (Letter). J Am Acad Dermatol (2005); 53: 909.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>909</start></extent></part><relatedItem type="host"><titleInfo><title>J Am Acad Dermatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>53</number></detail><extent unit="pages"><start>909</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit290"><titleInfo><title>Ocular side‐effects of tolterodine and oxybutynin, a single‐blind prospective randomized trial (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Leung DYL, Kwong YYY, Lam DSC. Ocular side‐effects of tolterodine and oxybutynin, a single‐blind prospective randomized trial (Letter). Br J Clin Pharmacol (2005); 60: 668.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>668</start></extent></part><relatedItem type="host"><titleInfo><title>Br J Clin Pharmacol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>668</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit291"><titleInfo><title>Safety and cardiac chronotropic responsiveness to the early injection of atropine during dobutamine stress echocardiography in the elderly</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsutsui JM, Lario FC, Fernandes DR, Kowatsch I, Sbano JC, Ramires JAF, Mathias W. Safety and cardiac chronotropic responsiveness to the early injection of atropine during dobutamine stress echocardiography in the elderly. Heart (2005); 91: 1563.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>1563</start></extent></part><relatedItem type="host"><titleInfo><title>Heart</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>91</number></detail><extent unit="pages"><start>1563</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit292"><titleInfo><title>Efficacy and systemic side‐effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Uusitalo H, Nino J, Tahvanainen K, Turjanmaa V, Ropo A, Tuominen J, Kahonen M. Efficacy and systemic side‐effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta Ophthalmol Scand (2005); 83: 723.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>723</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Ophthalmol Scand</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>723</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit293"><titleInfo><title>14. Respiratory System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit294"><titleInfo><title>Bronchospasm induced by inhalant corticosteroids: The role of ethanol</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Antonicelli L, Micucci C, Bonifazi F. Bronchospasm induced by inhalant corticosteroids: The role of ethanol. Allergy (2005); 61: 146.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>146</start></extent></part><relatedItem type="host"><titleInfo><title>Allergy</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>146</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit295"><titleInfo><title>The efficacy and safety of fluticasone propionate in very young children with persistent asthma symptoms</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Carlsen KCL, Stick S, Kamin W, Cirule I, Hughes S, Wixon C. The efficacy and safety of fluticasone propionate in very young children with persistent asthma symptoms. Respir Med (2005); 99: 1393.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>1393</start></extent></part><relatedItem type="host"><titleInfo><title>Respir Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>99</number></detail><extent unit="pages"><start>1393</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit296"><titleInfo><title>Safety of intravenous terbutaline in acute severe asthma: A retrospective study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kambalapalli M, Nichani S, Upadhyayula S. Safety of intravenous terbutaline in acute severe asthma: A retrospective study. Acta Paediatr (2005); 94: 1214.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>1214</start></extent></part><relatedItem type="host"><titleInfo><title>Acta Paediatr</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>94</number></detail><extent unit="pages"><start>1214</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit297"><titleInfo><title>Evaluation of the safety and efficacy of levalbuterol in 2‐5‐year‐old patients with asthma</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Skoner DP, Greos LS, Kim KT, Roach JM, Parsey M, Baumgartner RA. Evaluation of the safety and efficacy of levalbuterol in 2‐5‐year‐old patients with asthma. Pediatr Pulmonol (2005); 40: 477.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>477</start></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Pulmonol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>477</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit298"><titleInfo><title>15. Neuromuscular Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit299"><titleInfo><title>Beware of the residual curarization! (Editorial) (French)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baillard C. Beware of the residual curarization! (Editorial) (French). Ann Fr Anesth Reanim (2005); 24: 1245.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>1245</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Fr Anesth Reanim</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>1245</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit300"><titleInfo><title>Residual neuromuscular blockade (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Beaussier M, Boughaba MA. Residual neuromuscular blockade (French, English Abstract). Ann Fr Anesth Reanim (2005); 24: 1266.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>1266</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Fr Anesth Reanim</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>1266</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit301"><titleInfo><title>‘Botulinum toxin A dosage: Autonomic function as a measure of side effects’ (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Robertshaw K, Watson L, Parkin T, Morton RE. ‘Botulinum toxin A dosage: Autonomic function as a measure of side effects’ (Letter). Dev Med Child Neurol (2005); 47: 792.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>792</start></extent></part><relatedItem type="host"><titleInfo><title>Dev Med Child Neurol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>792</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit302"><titleInfo><title>Is botulinum toxin type A a safe and effective treatment for neurogenic urinary incontinence?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sahai A, Dasgupta P. Is botulinum toxin type A a safe and effective treatment for neurogenic urinary incontinence?. Nat Clin Pract Urol (2005); 2: 530.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>530</start></extent></part><relatedItem type="host"><titleInfo><title>Nat Clin Pract Urol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>2</number></detail><extent unit="pages"><start>530</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit303"><titleInfo><title>16. Reproductive System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit304"><titleInfo><title>Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17β‐estradiol/trimegestone versus 1 or 2 mg 17β‐estradiol/norethisterone acetate in postmenopausal women</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bouchard P, De Cicco‐Nardone F, Spielmann D, Garcea N. Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17β‐estradiol/trimegestone versus 1 or 2 mg 17β‐estradiol/norethisterone acetate in postmenopausal women. Gynecol Endocrinol (2005); 21: 142.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>142</start></extent></part><relatedItem type="host"><titleInfo><title>Gynecol Endocrinol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>21</number></detail><extent unit="pages"><start>142</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit305"><titleInfo><title>Ischemic colitis associated with naratriptan and oral contraceptive use: A rebuttal</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Charles JA. Ischemic colitis associated with naratriptan and oral contraceptive use: A rebuttal. Headache (2005); 45: 1419.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1419</start></extent></part><relatedItem type="host"><titleInfo><title>Headache</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1419</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit306"><titleInfo><title>Fatal venous thromboembolism associated with different combined oral contraceptives ‐ A study of incidences and potential biases in spontaneous reporting</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hedenmalm K, Samuelsson E. Fatal venous thromboembolism associated with different combined oral contraceptives ‐ A study of incidences and potential biases in spontaneous reporting. Drug Saf (2005); 28: 907.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>907</start></extent></part><relatedItem type="host"><titleInfo><title>Drug Saf</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>907</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit307"><titleInfo><title>Ischemic colitis associated with naratriptan and oral contraceptive use: A response</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Malone TD, Kori SH. Ischemic colitis associated with naratriptan and oral contraceptive use: A response. Headache (2005); 45: 1418.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1418</start></extent></part><relatedItem type="host"><titleInfo><title>Headache</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>45</number></detail><extent unit="pages"><start>1418</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit308"><titleInfo><title>Expanded phase I safety and acceptability study of 6% cellulose sulfate vaginal gel</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Malonza IM, Mirembe F, Nakabiito C, Odusoga LO, Osinupebi OA, Hazari K, Chitlange S, Ali MM, Callahan M, Van Damme L. Expanded phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS (2005); 19: 2157.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>2157</start></extent></part><relatedItem type="host"><titleInfo><title>AIDS</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>2157</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit309"><titleInfo><title>Potential failure of contraceptive efficacy in a patient taking methotrexate (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Prabu A, Bhosle J, Duddy MJ, Thomas AMC, Rankin ECC. Potential failure of contraceptive efficacy in a patient taking methotrexate (Letter). Rheumatology (2005); 44: 1461.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1461</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1461</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit310"><titleInfo><title>Postmenopausal hormone therapy ‐ Does it cause incontinence?</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Steinauer JE, Waetjen LE, Vittinghoff E, Subak LL, Hulley SB, Grady D, Lin F, Brown JS. Postmenopausal hormone therapy ‐ Does it cause incontinence?. Obstet Gynecol (2005); 106: 940.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>940</start></extent></part><relatedItem type="host"><titleInfo><title>Obstet Gynecol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>940</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit311"><titleInfo><title>Combined estradiol/gestodene and acute pancreatitis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Trenque‐Tessereau MGB, Picot C, Herment N, Trenque TC. Combined estradiol/gestodene and acute pancreatitis (Letter). Ann Pharmacother (2005); 39: 1953.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1953</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1953</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit312"><titleInfo><title>Potential failure of contraceptive efficacy in a patient taking methotrexate (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Williamson L, Yein K. Potential failure of contraceptive efficacy in a patient taking methotrexate (Letter). Rheumatology (2005); 44: 1461.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1461</start></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1461</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit313"><titleInfo><title>17. Gastrointestinal System Agents</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit314"><titleInfo><title>Cytolitic hepatitis and esomeprazole during chemotherapy (French, English Abstract)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Capitain O, Lortholary A, Abadir‐Lacourtoisie S. Cytolitic hepatitis and esomeprazole during chemotherapy (French, English Abstract). Presse Med (2005); 34: 1235.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>1235</start></extent></part><relatedItem type="host"><titleInfo><title>Presse Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>1235</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit315"><titleInfo><title>Proton pump inhibitor formulary considerations in the acutely ill. part 2: Clinically efficacy, safety, and economics</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. part 2: Clinically efficacy, safety, and economics. Ann Pharmacother (2005); 39: 1844.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1844</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Pharmacother</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>1844</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit316"><titleInfo><title>Gastric fundal polyps with cellular atypia in a patient using esomeprazole (Nexium)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Flick AL. Gastric fundal polyps with cellular atypia in a patient using esomeprazole (Nexium). Dig Dis Sci (2005); 50: 2100.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>2100</start></extent></part><relatedItem type="host"><titleInfo><title>Dig Dis Sci</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>2100</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit317"><titleInfo><title>Fatal toxic epidermal necrolysis due to lansoprazole (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Revuz J. Fatal toxic epidermal necrolysis due to lansoprazole (Letter). Clin Exp Dermatol (2006); 31: 148.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>148</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Dermatol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>148</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit318"><titleInfo><title>A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tack J, Muller‐Lissner S, Bytzer P, Corinaldesi R, Chang L, Viegas A, Schnekenbuehl S, Dunger‐Baldauf C, Rueegg P. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut (2005); 54: 1707.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>1707</start></extent></part><relatedItem type="host"><titleInfo><title>Gut</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>1707</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit319"><titleInfo><title>Association of inosine triphosphatase 94C>A and thiopurine S‐methyltransferase deficiency with adverse events and study drop‐outs under azathioprine therapy in a prospective Crohn disease study</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Von Ahsen N, Armstrong VW, Behrens C, Von Tirpitz C, Stallmach A, Herfarth H, Stein J, Bias P, Adler G, Shipkova M, Oellerich M, Kruis W, Reinshagen M. Association of inosine triphosphatase 94C>A and thiopurine S‐methyltransferase deficiency with adverse events and study drop‐outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem (2005); 51: 2282.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>2282</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Chem</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>51</number></detail><extent unit="pages"><start>2282</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit320"><titleInfo><title>18. Anti‐inflammatory Agents ‐ Steroidal</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit321"><titleInfo><title>Do steroids increase lymphoma risk? A case‐control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Askling J, Klareskog L, Hjalgrim H, Baecklund E, Bjorkholm M, Ekbom A. Do steroids increase lymphoma risk? A case‐control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis. Ann Rheum Dis (2005); 64: 1765.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>1765</start></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><extent unit="pages"><start>1765</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit322"><titleInfo><title>Precipitation of generalized pustular psoriasis by prednisolone (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Elston GE, Charles‐Holmes R, Carr RA. Precipitation of generalized pustular psoriasis by prednisolone (Letter). Clin Exp Dermatol (2006); 31: 133.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>133</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Exp Dermatol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>133</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit323"><titleInfo><title>Conjunctival necrosis following intravitreal injection of triamcinolone acetonide</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Srinivasan S, Prasad S. Conjunctival necrosis following intravitreal injection of triamcinolone acetonide. Cornea (2005); 24: 1027.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>1027</start></extent></part><relatedItem type="host"><titleInfo><title>Cornea</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>1027</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit324"><titleInfo><title>Refractory severe ocular hypertension after intravitreal triamcinolone acetonide injection</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yang CS, Chen MJ, Chou CK, Hsu WM. Refractory severe ocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmologica (2005); 219: 413.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>219</number></detail><extent unit="pages"><start>413</start></extent></part><relatedItem type="host"><titleInfo><title>Ophthalmologica</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>219</number></detail><extent unit="pages"><start>413</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit325"><titleInfo><title>19. Teratogens/fetal exposure</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit326"><titleInfo><title>Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baumgart DC, Sturm A, Wiedenmann B, Dignass AU. Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis (Letter). Gut (2005); 54: 1822.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>1822</start></extent></part><relatedItem type="host"><titleInfo><title>Gut</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>1822</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit327"><titleInfo><title>Spinal anaesthesia for Caesarean section and fetal acidosis (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Clyburn P. Spinal anaesthesia for Caesarean section and fetal acidosis (Reply). Anaesthesia (2005); 60: 1239.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1239</start></extent></part><relatedItem type="host"><titleInfo><title>Anaesthesia</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1239</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit328"><titleInfo><title>Spinal anaesthesia for Caesarean section and fetal acidosis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Collis RE, Harries SE. Spinal anaesthesia for Caesarean section and fetal acidosis (Letter). Anaesthesia (2005); 60: 1238.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1238</start></extent></part><relatedItem type="host"><titleInfo><title>Anaesthesia</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1238</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit329"><titleInfo><title>Ephedrine, phenylephrine and fetal acidosis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cooper DW. Ephedrine, phenylephrine and fetal acidosis (Letter). Anaesthesia (2005); 60: 1237.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1237</start></extent></part><relatedItem type="host"><titleInfo><title>Anaesthesia</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1237</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit330"><titleInfo><title>Hypospadias in sons of women exposed to diethylstilbestrol: A true trans‐generational effect? (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jouannic JM, Benifla JL. Hypospadias in sons of women exposed to diethylstilbestrol: A true trans‐generational effect? (Letter). Prenat Diagn (2005); 25: 1071.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1071</start></extent></part><relatedItem type="host"><titleInfo><title>Prenat Diagn</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><extent unit="pages"><start>1071</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit331"><titleInfo><title>Third‐trimester maternal toxicity with nevirapine use in pregnancy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Joy U, Poi M, Hughes L, Brady MT, Koletar SL, Para MF, Fan‐Havard P. Third‐trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol (2005); 106: 1032.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>1032</start></extent></part><relatedItem type="host"><titleInfo><title>Obstet Gynecol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>1032</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit332"><titleInfo><title>Neonatal signs after in utero exposure to selective serotonin reuptake inhibitors (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kaye BA, Weinstein J. Neonatal signs after in utero exposure to selective serotonin reuptake inhibitors (Letter). JAMA (2005); 294: 2299.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2299</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2299</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit333"><titleInfo><title>Using antidepressants during pregnancy (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Koren G, Matsui D, Einarson A, Knopper D, Steiner M. Using antidepressants during pregnancy (Reply). Can Med Assoc J (2005); 173: 1205.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>173</number></detail><extent unit="pages"><start>1205</start></extent></part><relatedItem type="host"><titleInfo><title>Can Med Assoc J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>173</number></detail><extent unit="pages"><start>1205</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit334"><titleInfo><title>Neonatal signs after in utero exposure to selective serotonin reuptake inhibitors (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lavenstein B. Neonatal signs after in utero exposure to selective serotonin reuptake inhibitors (Letter). JAMA (2005); 294: 2300.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2300</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2300</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit335"><titleInfo><title>Recombinant human erythropoietin in a triplet pregnancy ‐ A case report</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lialios G, Kallitsaris A, Bourantas KL, Messinis IE. Recombinant human erythropoietin in a triplet pregnancy ‐ A case report. J Reprod Med (2005); 50: 863.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>863</start></extent></part><relatedItem type="host"><titleInfo><title>J Reprod Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>863</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit336"><titleInfo><title>Risks associated with selective serotonin reuptake inhibitors in pregnancy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol (2005); 106: 1289.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>1289</start></extent></part><relatedItem type="host"><titleInfo><title>Obstet Gynecol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>1289</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit337"><titleInfo><title>Neonatal signs after in utero exposure to selective serotonin reuptake inhibitors (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Moses‐Kolko EL, Bogen D, Perel J, Wisner KL, Bregar A, Uhl K, Levin B. Neonatal signs after in utero exposure to selective serotonin reuptake inhibitors (Reply). JAMA (2005); 294: 2300.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2300</start></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>294</number></detail><extent unit="pages"><start>2300</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit338"><titleInfo><title>Life‐threatening maternal and fetal macrocytic anemia from antiretroviral therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Myers SA, Torrente S, Hinthorn D, Clark PL. Life‐threatening maternal and fetal macrocytic anemia from antiretroviral therapy. Obstet Gynecol (2005); 106: 1189.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>1189</start></extent></part><relatedItem type="host"><titleInfo><title>Obstet Gynecol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>106</number></detail><extent unit="pages"><start>1189</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit339"><titleInfo><title>Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Newport DJ, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN. Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy. Am J Psychiatry (2005); 162: 2162.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>162</number></detail><extent unit="pages"><start>2162</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Psychiatry</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>162</number></detail><extent unit="pages"><start>2162</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit340"><titleInfo><title>Spinal anaesthesia for Caesarean section and fetal acidosis (Reply)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Reynolds F. Spinal anaesthesia for Caesarean section and fetal acidosis (Reply). Anaesthesia (2005); 60: 1240.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1240</start></extent></part><relatedItem type="host"><titleInfo><title>Anaesthesia</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1240</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit341"><titleInfo><title>Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II receptor‐antagonists</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vendemmia M, Garcia‐Meric P, Rizzotti A, Boubred F, Lacroze V, Liprandi A, Simeoni U. Fetal and neonatal consequences of antenatal exposure to type 1 angiotensin II receptor‐antagonists. J Matern‐Fetal Neonatal Med (2005); 18: 137.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>137</start></extent></part><relatedItem type="host"><titleInfo><title>J Matern‐Fetal Neonatal Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>137</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit342"><titleInfo><title>Paroxetine (Paxil) and congenital malformations</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Williams M, Wooltorton E. Paroxetine (Paxil) and congenital malformations. Can Med Assoc J (2005); 173: 1320.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>173</number></detail><extent unit="pages"><start>1320</start></extent></part><relatedItem type="host"><titleInfo><title>Can Med Assoc J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>173</number></detail><extent unit="pages"><start>1320</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit343"><titleInfo><title>Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wogelius P, Norgaard M, Gislum M, Pedersen L, Schonheyder HC, Sorensen HT. Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones. Int J Antimicrob Agents (2005); 26: 323.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>323</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Antimicrob Agents</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>323</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit344"><titleInfo><title>Using antidepressants during pregnancy (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zitner D, Bischoff A. Using antidepressants during pregnancy (Letter). Can Med Assoc J (2005); 173: 1205.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>173</number></detail><extent unit="pages"><start>1205</start></extent></part><relatedItem type="host"><titleInfo><title>Can Med Assoc J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>173</number></detail><extent unit="pages"><start>1205</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit345"><titleInfo><title>20. Others</title></titleInfo><genre>other</genre></relatedItem><relatedItem type="references" displayLabel="cit346"><titleInfo><title>A case of lipoatrophy with insulin glargine (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ampudia‐Blasco FJ, Girbes J, Carmena R. A case of lipoatrophy with insulin glargine (Letter). Diabetes Care (2005); 28: 2983.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>2983</start></extent></part><relatedItem type="host"><titleInfo><title>Diabetes Care</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>2983</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit347"><titleInfo><title>Type III allergy to insulin detemir (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Darmon P, Castera V, Koeppel MC, Petitjean C, Dutour A. Type III allergy to insulin detemir (Letter). Diabetes Care (2005); 28: 2980.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>2980</start></extent></part><relatedItem type="host"><titleInfo><title>Diabetes Care</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>2980</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit348"><titleInfo><title>Anaphylactoid reaction after verteporfin therapy</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Doshi AB, Moshfeghi DM, Jack RL. Anaphylactoid reaction after verteporfin therapy. Am J Ophthalmol (2005); 140: 936.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>140</number></detail><extent unit="pages"><start>936</start></extent></part><relatedItem type="host"><titleInfo><title>Am J Ophthalmol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>140</number></detail><extent unit="pages"><start>936</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit349"><titleInfo><title>Safety and efficacy of risedronate in patients with age‐related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age‐related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials. J Bone Miner Res (2005); 20: 2105.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>2105</start></extent></part><relatedItem type="host"><titleInfo><title>J Bone Miner Res</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>2105</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit350"><titleInfo><title>Urinary excretion of vasoactive factors following contrast media exposure in humans</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Murakami R, Kumazaki T, Tajima H, Hayashi H, Kuwako T, Hakozaki K, Kiriyama T. Urinary excretion of vasoactive factors following contrast media exposure in humans. Nephron Clin Pract (2005); 101: 150.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>101</number></detail><extent unit="pages"><start>150</start></extent></part><relatedItem type="host"><titleInfo><title>Nephron Clin Pract</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>101</number></detail><extent unit="pages"><start>150</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit351"><titleInfo><title>Propylthiouracil‐induced lupus‐like syndrome: Successful management with oral corticosteroids (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ozkan HA, Ozkalemkas F, Ozkocaman V, Ozcelik T. Propylthiouracil‐induced lupus‐like syndrome: Successful management with oral corticosteroids (Letter). Thyroid (2005); 15: 1203.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>1203</start></extent></part><relatedItem type="host"><titleInfo><title>Thyroid</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>1203</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit352"><titleInfo><title>Risedronate‐induced intravascular haemolysis complicated by acute tubular necrosis (Letter)</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ozkurt ZN, Guliter S, Keles I, Keles H. Risedronate‐induced intravascular haemolysis complicated by acute tubular necrosis (Letter). Clin Rheumatol (2005); 24: 665.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>665</start></extent></part><relatedItem type="host"><titleInfo><title>Clin Rheumatol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>665</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit353"><titleInfo><title>Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra‐rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis</title></titleInfo><name type="personal"><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rossi RE, Monasterolo G, Coco G, Operti D. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra‐rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis. Int Arch Allergy Immunol (2005); 138: 105.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>138</number></detail><extent unit="pages"><start>105</start></extent></part><relatedItem type="host"><titleInfo><title>Int Arch Allergy Immunol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>138</number></detail><extent unit="pages"><start>105</start></extent></part></relatedItem></relatedItem><identifier type="istex">2BCF9D936A34E785E998F7ED585930ADCE5DC2FD</identifier><identifier type="ark">ark:/67375/WNG-SXHJF67B-7</identifier><identifier type="DOI">10.1002/pds.1178</identifier><identifier type="ArticleID">PDS1178</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2006 John Wiley & Sons, Ltd.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-SXHJF67B-7/record.json</uri></json:item></metadata><author></author><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C34 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002C34 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:2BCF9D936A34E785E998F7ED585930ADCE5DC2FD
|texte= Current awareness: Pharmacoepidemiology and drug safety
}}
| This area was generated with Dilib version V0.6.33. |  |